



**Center for Vaccine Ethics & Policy (CVEP)**  
**Vaccines and Global Health: The Week in Review**  
**24 January 2026 :: Issue 829**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)***
- :: [WHO](#)***
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)***
- :: [Organization Announcements](#)***
- :: [Journal Watch](#)***
- :: [Pre-Print Servers](#)***
- :: [Think Tanks](#)***
- :: [Public Consultations/Call for Inputs/Call for Papers](#)***

***Vaccines and Global Health: The Week in Review resumes publication following a medical leave for the Editor***

## **Milestones, Perspectives**

:::::::  
:::::::

### **WHO – 158th session of the Executive Board**

**2–7 February 2026**

Main Documents [selected]

[EB158/1](#)

Provisional agenda

[EB158/1 \(annotated\)](#)

Provisional agenda (annotated)

[EB158/8](#)

Immunization Agenda 2030

Mid-term review

[EB158/23](#)

Poliomyelitis

[EB158/44](#)

Reform of the global health architecture and the UN80 initiative

:::::::  
:::::::

## **WHO: Formal Withdrawal by U.S.**

### **WHO statement on notification of withdrawal of the United States**

24 January 2026

*Statement [Editor's text bolding]*

**As a founding member of the World Health Organization (WHO), the United States of America has contributed significantly to many of WHO's greatest achievements**, including the eradication of smallpox, and progress against many other public health threats including polio, HIV, Ebola, influenza, tuberculosis, malaria, neglected tropical diseases, antimicrobial resistance, food safety and more.

**WHO therefore regrets the United States' notification of withdrawal from WHO – a decision that makes both the United States and the world less safe. The notification of withdrawal raises issues that will be considered by the WHO Executive Board at its regular meeting starting on 2 February and by the World Health Assembly at its annual meeting in May 2026.**

**WHO takes note of statements from the government of the United States that say WHO has “trashed and tarnished” and insulted it, and compromised its independence. The reverse is true. As we do with every Member State, WHO has always sought to engage with the United States in good faith, with full respect for its sovereignty.**

In its statements, the United States cited as one of the reasons for its decision, “WHO failures during the COVID-19 pandemic”, including “obstructing the timely and accurate sharing of critical information” and that WHO “concealed those failures”. While no organization or government got everything right, WHO stands by its response to this unprecedented global health crisis. Throughout the pandemic, WHO acted quickly, shared all information it had rapidly and transparently with the world, and advised Member States on the basis of the best available evidence. WHO recommended the use of masks, vaccines and physical distancing, but at no stage recommended mask mandates, vaccine mandates or

lockdowns. We supported sovereign governments to make decisions they believed were in the best interests of their people, but the decisions were theirs.

Immediately after receiving the first reports of a cluster of cases of “pneumonia of unknown cause” in Wuhan, China on 31 December 2019, WHO asked China for more information and activated its emergency incident management system. By the time the first death was reported from China on 11 January 2020, WHO had already alerted the world through formal channels, public statements and social media, convened global experts, and published comprehensive guidance for countries on how to protect their populations and health systems. When the WHO Director-General declared COVID-19 a public health emergency of international concern under the International Health Regulations on 30 January 2020 – the highest level of alarm under international health law – outside of China there were fewer than 100 reported cases, and no reported deaths.

In the first weeks and months of the pandemic, the Director-General urged all countries repeatedly to take immediate action to protect their populations, warning that “the window of opportunity is closing”, “this is not a drill” and describing COVID-19 as “public enemy number one”.

In response to the multiple reviews of the COVID-19 pandemic, including of WHO’s performance, WHO has taken steps to strengthen its own work, and to support countries to bolster their own pandemic preparedness and response capacities. The systems we developed and managed before, during and after the emergency phase of the pandemic, and which run 24/7, have contributed to keeping all countries safe, including the United States.

**The United States also said in its statements that WHO has “pursued a politicized, bureaucratic agenda driven by nations hostile to American interests”. This is untrue.** As a specialized agency of the United Nations, governed by 194 Member States, WHO has always been and remains impartial and exists to serve all countries, with respect for their sovereignty, and without fear or favour.

WHO appreciates the support and continued engagement of all its Member States, which continue to work within the framework of WHO to pursue solutions to the world’s biggest health threats, both communicable and noncommunicable. Most notably, WHO Member States last year adopted the WHO Pandemic Agreement, which once ratified will become a landmark instrument of international law to keep the world safer from future pandemics. Member States are now negotiating an annex to the WHO Pandemic Agreement, the Pathogen Access and Benefit Sharing system, which if adopted will promote rapid detection and sharing of pathogens with pandemic potential, and equitable and timely access to vaccines, therapeutics and diagnostics.

**We hope that in the future, the United States will return to active participation in WHO.**

Meanwhile, WHO remains steadfastly committed to working with all countries in pursuit of its core mission and constitutional mandate: the highest attainable standard of health as a fundamental right for all people.

.....

.....

### **United States Completes WHO Withdrawal**

WASHINGTON — January 22, 2026 — The U.S. Department of Health and Human Services and the U.S. Department of State today announced the United States’ completion of its withdrawal from the World Health Organization (WHO) due to the organization’s mishandling of the COVID-19 pandemic that arose out of Wuhan, China, its failure to adopt urgently needed reforms, and its inability to demonstrate independence from the inappropriate political influence of WHO member states.

Health and Human Services Secretary Robert F. Kennedy, Jr. and Secretary of State Marco Rubio issued a joint statement on the termination of U.S. membership in the WHO.

President Trump on January 20, 2025, announced the U.S. plan to leave the WHO. During the yearlong process, the U.S. stopped funding WHO, withdrew all personnel from WHO, and began pivoting activities previously conducted with WHO to direct bilateral engagements with other countries and organizations. With the exit from WHO, the U.S. will be coordinating with WHO solely in a limited fashion to effectuate withdrawal.

The WHO delayed declaring a global public health emergency and a pandemic during the early stages of COVID-19, costing the world critical weeks as the virus spread. During that period, WHO leadership echoed and praised China's response despite evidence of early underreporting, suppression of information and delays in confirming human-to-human transmission. The organization also downplayed asymptomatic transmission risks and failed to promptly acknowledge airborne spread.

After the pandemic, the WHO did not adopt meaningful reforms to address political influence, governance weaknesses or poor coordination, reinforcing concerns that politics took priority over rapid, independent public health action and eroding global trust. Its report evaluating the possible origins of COVID-19 rejected the possibility that scientists created the virus, even though China refused to provide genetic sequences from individuals infected early in the pandemic and information on the Wuhan laboratories' activities and biosafety conditions.

The U.S. is the world's leading force in protecting public health, saving lives, and responding rapidly to infectious disease outbreaks. Going forward, the U.S. government will continue its global health leadership through existing and new engagements directly with other countries, the private sector, non-governmental organizations, and faith-based entities. U.S.-led efforts will prioritize emergency response, biosecurity coordination, and health innovation to protect America first while delivering benefits to partners around the world.

Read Fact Sheet: [U.S. Withdrawal from the World Health Organization.](#)

:::::::

#### **Joint Statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy, Jr.**

*Joint Statement January 22, 2026 [Editor's text bolding]*

**Today, the United States withdrew from the World Health Organization (WHO), freeing itself from its constraints**, as President Trump promised on his first day in office by signing E.O. 14155. This action responds to the **WHO's failures during the COVID-19 pandemic and seeks to rectify the harm from those failures inflicted on the American people**. Promises made, promises kept.

Like many international organizations, the WHO abandoned its core mission and acted repeatedly against the interests of the United States. Although the United States was a founding member and the WHO's largest financial contributor, the organization pursued a politicized, bureaucratic agenda driven by nations hostile to American interests. In doing so, the WHO obstructed the timely and accurate sharing of critical information that could have saved American lives and then concealed those failures under the pretext of acting "in the interest of public health."

**Even on our way out of the organization, the WHO tarnished and trashed everything that America has done for it. The WHO refuses to hand over the American flag** that hung in front of it, arguing it has not approved our withdrawal and, in fact, claims that we owe it compensation.

From our days as its primary founder, primary financial backer, and primary champion until now, our final day, the insults to America continue.

**Going forward, U.S. engagement with the WHO will be limited strictly to effectuate our withdrawal and to safeguard the health and safety of the American people. All U.S. funding for, and staffing of, WHO initiatives has ceased.** The United States will continue to lead the world in public health, saving millions of lives and protecting Americans at home by preventing infectious disease threats from reaching our shores while advancing global health security through direct, bilateral, and results-driven partnerships. We will continue to work with countries and trusted health institutions to share best practices, strengthen preparedness, and protect our communities through a more focused, transparent, and effective model which delivers real outcomes rather than the bloated and inefficient bureaucracy of the WHO.

**Today, we right these injustices and bring an end to the bureaucratic inertia, entrenched paradigms, conflicts of interest, and international politics that have rendered the organization beyond repair.** We will get our flag back for the Americans who died alone in nursing homes, the small businesses devastated by WHO-driven restrictions, and the American lives shattered by this organization's inactivity. Our withdrawal is for them.

:::::::

:::::::

## **WHO Pandemic Agreement – PABS**

### **[Countries progress negotiations in support of WHO Pandemic Agreement](#)**

23 January 2026

*News release*

The World Health Organization (WHO) Member States this week advanced their negotiations on the Pathogen Access and Benefit-Sharing (PABS) system in a resumed session of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement. The PABS system is a core element of the agreement adopted by the World Health Assembly (WHA) in May 2025.

**During the session held on 20–22 January 2026, Member States continued text-based negotiations on outstanding issues in the draft annex and exchanged views aimed at narrowing differences and identifying areas of convergence.**

"I am encouraged by the progress we have made in several areas, with signs of emerging consensus for some parts of the Pathogen Access and Benefit-Sharing system," said IGWG Bureau co-chair Ambassador Tovar da Silva Nunes, of Brazil. "As we look ahead to the fifth session, the focus will be on the outstanding, complex issues. The resumed session has helped us gain a clearer picture of where we stand."

Established by the WHA, the IGWG is tasked, as a priority, with drafting and negotiating the PABS system, which is intended to enable safe, transparent and accountable sharing of pathogens with pandemic potential and their genetic sequence information, alongside the fair and equitable sharing of benefits arising from their use, including vaccines, therapeutics and diagnostics.

The resumed session was held following a request by Member States to extend the fourth meeting of the IGWG, which convened in December 2025...**Further meetings of the IGWG are scheduled in the coming months as Member States continue their negotiations.**

"A strong Pathogen Access and Benefit-Sharing system will be a cornerstone of a safer and more equitable world," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "I thank countries for their commitment to multilateral solutions."

**The outcome of IGWG's work will be submitted to the Seventy-ninth World Health Assembly in May 2026 for its consideration.**

:::::::

## **CCDC Weekly Reports: Current Volume (7)**

China CDC 2026-01-16 / No. 3

### **Commentary: Pathogen Access and Benefit-Sharing: Can the WHO Pandemic Agreement Bridge the Equity Divide?**

#### *Abstract*

The adoption of the WHO Pandemic Agreement in May 2025 marks a pivotal shift toward institutionalizing global pandemic governance. Anchored in principles of equity, solidarity, and human rights, the agreement establishes a Pathogen Access and Benefit-Sharing (PABS) System, which aims to ensure equitable access to pandemic-related health products (PRHPs). However, operational ambiguities — particularly in defining pathogen scope, integrating traditional knowledge, enforcing manufacturer obligations, and coordinating with multilateral frameworks like the Convention on Biological Diversity and the Nagoya Protocol — pose significant implementation risks. Crucially, the agreement's effectiveness is intertwined with broader health system resilience. However, specific provisions for PABS integration within a strengthened health system architecture remain underdeveloped. Moreover, critical gaps persist regarding financing, compliance, One Health integration, digital governance, community engagement, and alignment with broader health systems. The success of the agreement hinges on resolving these gaps through subsequent protocols and sustained political commitment.

The coronavirus disease 2019 (COVID-19) pandemic has exposed some critical flaws in global health security, such as fragmented supply chains, vaccine nationalism, and systemic inequities in accessing diagnostics, therapeutics, and vaccines (1). Consequently, World Health Organization (WHO) member states initiated negotiations for a legally binding Pandemic Agreement in December 2021. After extensive deliberations, the agreement was adopted at the 78th World Health Assembly on May 20, 2025 (2). Its mandate is clear: transform ad hoc crisis responses into a cohesive, equity-driven framework for pandemic prevention, preparedness, and response. However, the success of this framework is intrinsically linked to underlying health system capacities and a broader preparedness ecosystem.

This commentary examines critical ambiguities within the Pathogen Access and Benefit-Sharing (PABS) mechanism established by the Pandemic Agreement. Key unresolved issues include defining pathogen scope (particularly those with zoonotic sources), enforcing manufacturer obligations for equitable product allocation, establishing transparent benefit-distribution criteria, and harmonizing the system with multilateral regimes such as the Convention on Biological Diversity (CBD) and the Nagoya Protocol. Furthermore, it explores foundational yet unaddressed issues, including specific compliance and financing models, the operationalization of One Health and digital equity principles, community-centric engagement frameworks, and mechanisms for resolving legal and ethical dilemmas arising from implementation. Future negotiations on the PABS operational protocol must urgently address these gaps to strengthen the mechanism and ensure effective implementation of the agreement.

:::::::

:::::::

## **Gavi CEO calls for global health leap**

- :: Gavi CEO Dr Sania Nishtar, writing in *The Lancet*, sets out a framework for radical reform of global health institutions
- :: Global health institutions should merge operations in countries in order to focus on generating global public goods, scaling impact and supporting the most fragile contexts, Dr Nishtar writes
- "" Dr Sania Nishtar: "We must move away from piecemeal reform and imagine a new system that places the needs of countries, not the institutions themselves, at its heart."

Geneva, 21 January 2026 – Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance today issues an urgent call to reform global health institutions. Writing in a Viewpoint article in The Lancet, Dr Nishtar argues that global health institutions (GHIs), collectively known as "the global health architecture", must be radically reformed to support the needs of countries.

A far-reaching reform process, or global health leap, Dr Nishtar writes, would not only protect the spectacular gains made across global health in past decades but also unlock further impact for years to come. Such a leap, Dr Nishtar continues, could be achieved if GHIs were to focus solely on activities that cannot be achieved by individual countries, for example generating global public goods, scaling impact and supporting people in fragile and conflict-affected contexts, with operations in countries merged and handed over to national governments to run.

"Our global health architecture, which has achieved so much in the past, is in crisis. We must move away from piecemeal reform and imagine a new system that places the needs of countries, not the institutions themselves, at its heart. Our urgent need now is for all stakeholders to come together and agree on principles, objectives and scope of reform," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance.

Gavi's own reform programme, the Gavi Leap, could serve as a blueprint for broader global health reform. By facilitating a historic shift in decision making power to countries, Gavi has been able to maintain its ambitious immunisation targets for its new five-year strategy period, despite a major reduction in funding and staff.

:::::::  
:::::::  
:::::::

## **Polio – PHEIC**

### **Polio this week** [21 January 2026]

*Headlines [Selected]*

#### ***Summary of new polioviruses this week:***

- :: Pakistan: one WPV1 case
- :: Germany: two WPV1-positive environmental samples
- :: Nigeria: nine cVDPV2 cases, one cVDPV2-positive environmental sample, and five cVDPV3 cases

:::::::

#### ***Contents [click to move among sections]***

- :: Milestones, Perspectives
- :: WHO
- :: U.S. Immunization and Public Health Governance/Policy/Funding
- :: Organization Announcements
- :: Journal Watch

:: [Pre-Print Servers](#)  
:: [Think Tanks](#)  
:: [Public Consultations/Call for Inputs/Call for Papers](#)

:::::::  
:::::::

### **WHO & Regional Offices [25 Jan 2026]**

<https://www.who.int/news>  
*Selected News/Announcements/Statements*  
24 January 2026  
*Statement*

#### **[WHO statement on notification of withdrawal of the United States](#)**

23 January 2026  
*News release*  
**[Countries progress negotiations in support of WHO Pandemic Agreement](#)**

:::::::

### **WHO Vaccines and Immunization [IVB]**

[https://www.who.int/health-topics/vaccines-and-immunization#tab=tab\\_1](https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1)  
*News*  
*No new digest content identified.*

:::::::

### **WHO Regional Offices**

*Selected Press Releases, Announcements*  
**[WHO African Region AFRO](#)**

*No new digest content identified.*

### **[WHO Region of the Americas PAHO](#)**

:: 16 Jan 2026

#### **[Measles elimination status in the United States and Mexico](#)**

Washington, D.C., 16 January 2026 (PAHO) — The Pan American Health Organization (PAHO) Regional Monitoring and Re-Verification Commission for Measles, Rubella, and Congenital Rubella Syndrome (RVC) has invited the United States and Mexico to meet virtually on April 13th, 2026, to review their measles elimination status. The meeting follows measles...

:: 14 Jan 2026

#### **[Drug use disorders a growing public health concern in the Americas, PAHO study finds](#)**

Washington, D.C., 14 January 2026 (PAHO) — Drug use disorders are a major and growing public health problem in the Americas. Drug use is among the top 10 risk factors contributing to all-cause mortality and disability in the Region, according to findings published in the Pan American Journal of Public Health. In 2021, an estimated 17.7 million...

:: 10 Jan 2026

#### **[PAHO issues alert on simultaneous circulation of seasonal influenza and respiratory syncytial virus in the Americas](#)**

Washington, D.C., January 10, 2026 (PAHO) — The Pan American Health Organization (PAHO) has urged countries across the Americas to remain vigilant and strengthen health system preparedness in response to the simultaneous circulation of seasonal influenza and respiratory syncytial virus (RSV). This situation could place additional pressure on...

## **WHO South-East Asia Region SEARO**

:: 13 January 2026 *News release*

**WHO South-East Asia marks 15 years since the last case of wild poliovirus; polio legacy continues to drive broader public health gains**

## **WHO European Region EURO**

*No new digest content identified.*

## **WHO Eastern Mediterranean Region EMRO**

**:: Rotary funds WHO to support Pakistan in protecting 27 million children against polio in high-risk districts**

21 January 2026

## **WHO Western Pacific Region**

*No new digest content identified.*

::::::

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

**Multi-country outbreak of mpox, External situation report #62 - 23 January 2026**

::::::

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

::::::

## **Weekly Epidemiological Record**

Vol. 101, No. 3, pp. 5-12 16 January 2026

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Summary of the Global report on neglected tropical diseases 2025

::::::

## **New WHO Publications**

<https://www.who.int/publications>

*Selected*

22 January 2026

**Health in immigration detention: evidence brief for policy and practice**

*Overview*

Immigration detention poses significant risks to health and well-being, yet its use is increasing globally. Migrants, asylum seekers and other noncitizens in immigration detention experience harmful social and environmental conditions in detention facilities, leading to negative health outcomes. Universal human rights standards and recommendations provided in the Global Compact for Safe, Orderly and Regular Migration require states to ensure detention to be a measure of last resort only, and never for children, but evidence shows these principles are not consistently upheld. This brief for policy and practice

reviews global evidence on health impacts of immigration detention, identifying key challenges and gaps. It calls for stronger safeguards, improved living conditions, timely health screening and care, supporting evidence-informed policies that uphold the right to health for all.

13 January 2026

[\*\*Advancing institutional compliance and continuous improvement in vaccine manufacturing: Virtual training...\*\*](#)

11 January 2026

[\*\*Malaria surveillance assessment toolkit: implementation reference guide, 2nd ed.\*\*](#)

9 January 2026

[\*\*Improved influenza vaccines: full value vaccine assessment\*\*](#)

... The FVVA examines the vaccine development pipeline, quantifies projected health and economic benefits, assesses financial viability for manufacturers, and identifies country preferences and implementation challenges. It provides a basis to guide investment, policy decisions, and introduction strategies – supporting stronger seasonal programs and enhanced pandemic preparedness.

Using a mixed-methods approach – including literature review, stakeholder engagement, and quantitative modeling – the FVVA estimates that broad use of improved vaccines could prevent 6.6–18 billion additional influenza cases, 2.3–6.2 million deaths, and 21–57 million disability-adjusted life years (DALYs) globally between 2025 and 2050. Economic modeling suggests cost-effectiveness of such vaccines in 9–48% of countries at the lowest assumed price point. The FVVA furthermore describes the proposed financial value to develop and commercialize improved influenza vaccines, in both established and emerging markets.

The FVVA emphasizes that collaboration among developers, manufacturers, donors, multilateral organizations, and policymakers is essential to maximize public health impact and strengthen global pandemic preparedness.

:::::::  
:::::::  
:::::::

## **Africa**

**Africa CDC** [25 Jan 2026]

<https://africacdc.org/>

*Press Releases, Statements [Selected]*

[\*\*Lifting of Mpox as a Public Health Emergency of Continental Security \(PHECS\)\*\*](#)

22 January 2026

Africa has officially lifted Mpox as a Public Health Emergency of Continental Security following recommendations from the Africa CDC Emergency Consultative Group. The decision highlights the continent's strengthened health security, effective leadership, regional cooperation, and successful international partnerships in managing complex public health challenges.

*Communiqué*

[\*\*Africa CDC Guidance for and clinical trial to be conducted in Africa\*\*](#)

22 January 2026

*Africa CDC has defined a comprehensive, Africa-relevant checklist of conditionalities that an external company (sponsor) must meet to conduct a vaccine clinical trial in an African country.*

:::::::  
:::::::

## China – CDC+

**National Health Commission of the People's Republic of China** [25 Jan 2026]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [25 Jan 2026]

<http://english.nmpa.gov.cn/>

*News*

**[NMPA to enhance drug regulation under revised rules — committed to a people-centered healthy policy and strengthen high-effect regulation](#)**

Updated: 2026-01-08

## China CDC

**CCDC Weekly Reports: Current Volume (7)**

**2026-01-23 / No. 4**

[PDF of this issue](#)

- [Preplanned Studies: Late HIV Diagnosis and Associated Factors Among Newly Reported HIV/AIDS Cases Aged ≥50 Years — China, 2022–2024](#)
- [Preplanned Studies: Impact of Hepatitis C Virus Co-infection on Antiretroviral Therapy Outcomes in Adults Living with HIV — China, 2002–2023](#)
- [Preplanned Studies: Increasing Uptake of Pre-Exposure Prophylaxis and Associated Behavioral Changes Among Men Who Have Sex with Men — Qingdao City, Shandong Province, China, 2024–2025](#)
- [Outbreak Reports: Imported Cases of Monkeypox Virus Clade Ia — China, 2025](#)

**2026-01-16 / No. 3**

[PDF of this issue](#)

- [Commentary: Pathogen Access and Benefit-Sharing: Can the WHO Pandemic Agreement Bridge the Equity Divide?](#)
- [Vital Surveillances: Analysis of Rabies Epidemiological Characteristics and Failed Post-Exposure Prophylaxis Cases — Hunan Province, China, 2019–2024](#)
- [Methods and Applications: Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus Neutralizing Antibodies — China, 2025](#)
- [Methods and Applications: Machine Learning Models for Predicting Latent Tuberculosis Infection Risk in Close Contacts of Patients with Pulmonary Tuberculosis — Henan Province, China, 2024](#)

:::::

:::::

## Europe

**European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

**[ECDC issues guidance on doxycycline for STI prevention](#)**

19 Jan 2026

**[Three new European Union reference laboratories are now operational](#)**

15 Jan 2026

*Surveillance and monitoring*

### **Diphtheria - Annual Epidemiological Report for 2023**

23 Jan 2026

In 2023, 216 cases of diphtheria due to toxigenic *Corynebacterium diphtheriae* (n=155) or *C. ulcerans* (n=61) were reported to ECDC. The increase of diphtheria among migrants reported in several EU/EEA countries in the second half of 2022 decreased to lower levels in 2023.

*Surveillance and monitoring*

### **Communicable disease threats report, 17-23 January 2026, week 4**

23 Jan 2026

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 January 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, avian influenza, and Marburg virus disease.

### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

*News & Press Releases*

### **EMA and FDA set common principles for AI in medicine development**

Advancing safe, ethical and aligned AI practices across the medicines lifecycle

14 January 2026

:::::::

:::::::

### **India**

### **National Centre for Disease Control**

*Directorate General of Health Services, Ministry of Health & Family Welfare*

*Announcements*

*No new digest content identified.*

:::::::

:::::::

:::::::

### **U.S. Immunization and Public Health Governance/Policy/Funding**

*Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive*

### **Executive Branch - White House, State, HHS, FDA, CDC+**

#### **White House**

*Presidential Actions – Executive Orders; Memoranda; Proclamations*

*No new digest content identified.*

### **Department of State**

*Press Releases - Selected*

*Joint Statement*

**Joint Statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy, Jr.**

January 22, 2026

*Press Statement*

**Driving Progress on the America First Global Health Strategy Through Bilateral Global Health MOU with Malawi**

Thomas "Tommy" Pigott January 14, 2026

**HHS**

*Press Room - Selected*

**NIH Proposes Embryonic Stem Cell Research Shift to Put Patients First**

January 23, 2026 Press Release

**WTAS: HHS Bars Research Using Human Fetal Tissue from Elective Abortions and Other Departmental Actions**

January 23, 2026 Press Release

**HHS Bars Research Using Human Fetal Tissue from Elective Abortions**

January 23, 2026 Press Release

**Joint Statement by Secretary of State Rubio and Secretary of Health and Human Services Kennedy on the Termination of U.S. Membership in the World Health Organization (WHO)**

January 22, 2026 Press Release

**United States Completes WHO Withdrawal**

January 22, 2026 Press Release

**Secretary Kennedy Appoints Two OB-GYNs to CDC's Advisory Committee on Immunization Practices**

WASHINGTON — JAN. 13, 2026 — The U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC) today announced the appointment of two new members to the CDC Advisory Committee on Immunization Practices (ACIP). These appointments reflect the commitment of Secretary Robert F. Kennedy, Jr. to transparency, gold standard science, and diverse expertise in guiding the nation's immunization policies. In June 2025, Secretary Kennedy reconstituted ACIP to restore public trust in vaccines.

The new members are:

Adam Urato, M.D., Obstetrician and Gynecologist specializing in Maternal-Fetal Medicine. Dr. Urato has held academic appointments at Harvard Medical School, the University of South Florida, and Tufts University School of Medicine. His clinical roles have included Maternal-Fetal Medicine attending positions at MetroWest Medical Center, Beth Israel Deaconess Medical Center, Boston Medical Center/St. Elizabeth's, and Tufts Medical Center. Dr. Urato received his B.A. from Harvard College and his M.D. from Harvard Medical School. He has also published extensively in peer-reviewed journals and participated in FDA advisory panels.

Kimberly Biss, M.D., Obstetrician and Gynecologist in St. Petersburg, Florida. Dr. Biss has held multiple hospital leadership positions at Bayfront Health/Orlando Health Bayfront Hospital, including Chief of Staff, Chairman of Obstetrics and Gynecology, and Medical Executive Board Officer. She is board-certified in Obstetrics and Gynecology and maintains membership in several professional medical associations. Dr. Biss received her M.D. from Tufts University School of Medicine. Her experience includes clinical education roles and publication on COVID-19 vaccine safety for pregnant women.

"ACIP serves as Americans' watchdog for vaccine safety and transparency," Secretary Kennedy said. "Dr. Urato and Dr. Biss bring the scientific credentials, clinical experience, and integrity this committee requires."

**NIH** [to 25 Jan 2026]

<http://www.nih.gov/>

*News Releases*

**NIH Announces Major Policy Shift to End Use of Human Fetal Tissue in NIH-Supported Research**

January 22, 2026 — Agency to focus on next-generation, validated research models.

**FDA**

*Press Announcements*

*FDA News Releases*

*No new digest content identified.*

**FDA CBER**

*What's New for Biologics*

*No new digest content identified.*

**FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]**

*Advisory Committee Calendar*

***No future meetings posted.***

**FDA Pediatric Advisory Committee Meeting**

*Advisory Committee Calendar*

***No future meetings posted.***

**CDC**

<http://www.cdc.gov/media/index.html>

*Latest News - Selected*

**United States Completes WHO Withdrawal**

Jan 22, 2026

**CDC – Immunization Safety Office (ISO)**

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

*No new digest content identified.*

**ACIP**

**2026 Meetings Schedule** *[no agenda content posted]*

- February 25-26
- June 24-25
- October 21-22

**Leading Public Health Groups Seek Expedited Injunctive Relief Against Immunization Schedule Changes, Upcoming ACIP Meeting; Hearing Scheduled Friday, February 13**

January 13, 2026

A group of medical professional societies, led by the American Academy of Pediatrics (AAP) and including the American Public Health Association (APHA), seek to enjoin the upcoming February 25-26 ACIP meeting and vacate recent changes to the pediatric immunization schedule. A hearing on plaintiffs' preliminary injunction is scheduled for Friday, February 13.

**National Vaccine Program Committee (NVAC)**

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

**No 2025 meeting dates posted.**

**Advisory Commission on Childhood Vaccines (ACCV)**

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

**ACCV Meeting – December 29, 2025****135th ACCV Meeting – December 29, 2025**

[135th ACCV meeting agenda](#) (PDF - 19 KB)

[Written Public Comments Received by December 23, 2025](#) (PDF - 1 MB)

**134th ACCV Meeting – December 29, 2025**

[134th ACCV meeting agenda](#) (PDF - 20 KB)

[Updates from Centers for Disease Control and Prevention \(CDC\)](#) (PDF - 590 KB)

[Updates from National Institutes of Health \(NIH\)](#) (PDF - 808 KB)

**133rd ACCV Meeting – December 29, 2025**

[133rd ACCV meeting agenda](#) (PDF - 20 KB)

[Overview of Department of Justice \(DOJ\)](#) (PDF - 9 MB)

[Report from Department of Justice \(DOJ\)](#) (PDF - 5 MB)

**132nd ACCV Meeting – December 29, 2025**

[132nd ACCV meeting agenda](#) (PDF - 40 KB)

[Overview and Updates of the National Vaccine Injury Compensation Program \(VICP\)](#) (PDF - 1 MB)

**MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

*No new digest content identified.*

:::::::

**NSF**

News

*No new digest content identified.*

:::::::

**U.S. Congress****House of Representatives**

*No new digest content identified.*

**U.S. Senate****Senate Health, Education, Labor, and Pensions (HELP) Committee**

*No new digest content identified.*

:::::::

**Supreme Court, Federal & Appellate Courts**

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

*No new digest content identified.*

:::::::  
:::::::  
:::::::

## **U.S. Medical Societies, Health Organizations**

*This inventory is evolving and may not capture all instances of relevant comment and analysis.*

### **American Academy of Family Physicians (AAFP)**

<https://www.aafp.org/news/media-center.html>

(Accessed 25 Jan 2026)

*No new digest content identified.*

### **American Academy of Pediatrics (AAP)**

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 25 Jan 2026)

*News*

#### [Leading Public Health Groups Seek Expedited Injunctive Relief Against Immunization Schedule Changes, Upcoming ACIP Meeting; Hearing Scheduled Friday, February 13](#)

January 13, 2026

A group of medical professional societies, led by the American Academy of Pediatrics (AAP) and including the American Public Health Association (APHA), seek to enjoin the upcoming February 25-26 ACIP meeting and vacate recent changes to the pediatric immunization schedule. A hearing on plaintiffs' preliminary injunction is scheduled for Friday, February 13.

### **American College of Physicians (ACP)**

<https://www.acponline.org/more-acp-news>

(Accessed 25 Jan 2026)

*News Releases*

#### [Leading public health groups seek expedited injunctive relief against immunization schedule changes, upcoming ACIP meeting; hearing scheduled Friday, February 13](#)

01/13/26

### **America's Health Insurance Plans (AHIP)**

<https://www.ahip.org/news>

(Accessed 25 Jan 2026)

*News*

*No new digest content identified.*

### **American Geriatrics Society (AGS)**

<https://www.americangeriatrics.org/media-center>

(Accessed 25 Jan 2026)

*Recent Press Releases*

*No new digest content identified.*

### **American Medical Association (AMA)**

<https://www.ama-assn.org/press-center>

(Accessed 25 Jan 2026)

*Press Releases*

Jan 23, 2026 ·

### **AMA statement on ACIP chair's comments on polio, routine vaccinations**

*Statement attributable to:*

*Sandra Adamson Fryhofer, MD, Trustee, American Medical Association*

"The American Medical Association is deeply alarmed by efforts to weaken long-standing evidence-based vaccine recommendations, including suggestions that polio vaccination should seemingly not be routinely recommended to patients.

"This is not a theoretical debate—it is a dangerous step backward. "Vaccines have saved millions of lives and virtually eliminated devastating diseases like polio in the United States. There is no cure for polio. When vaccination rates fall, paralysis, lifelong disability, and death return. The science on this is settled.

"Moving away from routine immunizations, which involves discussions between clinicians and patients, does not increase freedom—it increases suffering. It puts children, families, and entire communities at risk and undermines the public health protections that generations of Americans depend on.

"The AMA strongly urges policymakers to follow the evidence and the expertise of physicians and public health professionals. Weakening vaccine recommendations will cost lives, and that is a price our nation should not be willing to pay."

### **American Osteopathic Association (AOA)**

<https://osteopathic.org/news/>

(Accessed 25 Jan 2026)

*Latest News*

*No new digest content identified.*

### **American Public Health Association (APHA)**

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName>Newest&sortMode=desc>

(Accessed 25 Jan 2026)

### **Leading Public Health Groups Seek Expedited Injunctive Relief Against Immunization Schedule Changes, Upcoming ACIP Meeting; Hearing Scheduled Friday, February 13**

January 13, 2026

A group of medical professional societies, led by the American Academy of Pediatrics and including the American Public Health Association, seek to enjoin the upcoming February 25-26 ACIP meeting and vacate recent changes to the pediatric immunization schedule.

### **Infectious Diseases Society of America (IDSA)**

<https://www.idsociety.org/>

(Accessed 25 Jan 2026)

*News releases and statements*

### **Statement on U.S. withdrawal from WHO**

January 22, 2026

The U.S. withdrawal from the World Health Organization is a shortsighted and misguided abandonment of our global health commitments. Global cooperation and communication are critical to keep our own citizens protected because germs do not respect borders.

Whether facing emerging threats like Ebola or the persistent burden of annual flu outbreaks, international tracking is essential. By withdrawing from WHO, the U.S. will no longer participate in the

Global Influenza Surveillance and Response System, the vital platform for monitoring flu cases and sharing data and viral samples used to develop yearly flu vaccines. This will severely hamper efforts to match vaccines to circulating strains of flu.

Withdrawing from the World Health Organization is scientifically reckless. It fails to acknowledge the fundamental natural history of infectious diseases. Global cooperation is not a luxury; it is a biological necessity.

### **National Foundation for Infectious Diseases (NFID)**

<https://www.nfid.org/news-updates/>

(Accessed 25 Jan 2026)

*News and Updates*

January 16, 2026

#### **NFID Statement on mRNA Technology**

Restricting specific vaccine technologies would slow potentially lifesaving research and could discourage investment in future vaccine development

### **National Medical Association (NMA)**

<https://nmanet.org/blog/>

(Accessed 25 Jan 2026)

*Latest News*

#### **National Medical Association Rejects Proposal to Make Life-Saving Vaccines Optional**

January 23, 2026

*Statement attributable to:*

*Dr. Roger A. Mitchell, Jr., 126th President, National Medical Association*

The National Medical Association (NMA) strongly disagrees with recent comments from the Chair of the Advisory Committee on Immunization Practices (ACIP) suggesting that vaccines for polio, measles, and other infectious diseases should be optional.

Undercutting routine vaccination places the public at serious risk and threatens decades of progress in preventing disease, disability, and death. The measles and polio vaccines represent extraordinary public health achievements. Before the polio vaccine was widely administered in the United States, the virus caused approximately 15,000 cases of paralysis each year, primarily among children.

Any policy approach that would again place Americans at risk of paralysis from a completely preventable disease is irresponsible. As physicians committed to science and evidence-based medicine, we know there is no cure for paralytic polio. Treatment is limited to supportive care and rehabilitation. Prevention through vaccination remains the most effective and proven protection and has been validated through decades of use and research.

We urge lawmakers to intervene to prevent further erosion of our nation's public health infrastructure. Framing vaccination solely as an individual choice ignores the collective impact on communities. It also places the most vulnerable, including infants, immunocompromised individuals, and those who cannot be vaccinated, at unnecessary risk from diseases we have already learned how to effectively prevent.

### **Pediatric Infectious Diseases Society (PIDS)**

<https://pids.org/news-announcements/>

(Accessed 25 Jan 2026)

*News & Announcements*

*No new digest content identified.*

## **Society for Healthcare Epidemiology of America (SHEA)**

<https://shea-online.org/news/>

(Accessed 25 Jan 2026)

*No new digest content identified.*

## **Society for Maternal-Fetal Medicine (SMFM)**

<https://www.smfm.org/>

(Accessed 25 Jan 2026)

*News*

*No new digest content identified.*

:::::::

:::::::

## **Civil Society – Individuals, Organizations, Institutions *[Selected]***

:::::::

### **Kaiser Family Foundation/KFF [25 Jan 2026]**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

#### **State Recommendations for Routine Childhood Vaccines: Increasing Departure from Federal Guidelines**

Jan 22, 2026 *Policy Watch*

Starting in May of last year, HHS Secretary Kennedy and the CDC/ACIP began to make changes to the federal vaccine schedule for children, culminating in an announcement on January 5 of this year with the most wide-ranging changes to date. This policy brief tracks the number of states that have announced they are no longer following federal government recommendations for childhood vaccines as of January 20, 2026.

*... Findings*

**As of January 20, 2026, the majority of states (28 states, including DC) have announced that they will not follow the new CDC childhood vaccine recommendations for at least some childhood vaccines, instead relying on prior recommendations, state**

**recommendations, and/or those of external entities.** Most of these states have indicated that they will follow the recommendations of the independent medical association, the American Academy of Pediatrics (AAP). Among these are two inter-state public health alliances which previously formed to develop shared recommendations and have reaffirmed their intent to follow AAP guidelines: the West Coast Health Alliance, which includes California, Hawaii, Oregon, and Washington, and the Northeast Public Health Collaborative, which includes ten states and New York City.

**Almost all of these states (25 of 28) have announced that they will do so for all childhood vaccines.** Most of these states are choosing to follow non-federal guidelines for all childhood vaccines. The three states that are more limited are Alaska and Mississippi, which announced that they would continue to recommend the Hepatitis B vaccine at birth for all infants, even those whose mothers test negative (no longer recommended as routine by the CDC), and Arizona, which has announced that it will continue to recommend Hepatitis B at birth and COVID-19 vaccines consistent with guidelines from external entities.

**This marks a significant increase since September when only nine states had announced that they would not follow CDC/ACIP vaccine recommendations for all childhood vaccines (some also did so for adults).** In September, most states that had announced changes did so for COVID-19 only (13), which at that time, was the only vaccine for which changes had been made by the federal government (removing the routine vaccination recommendation generally, including for children). With the changing recommendation regarding Hepatitis B vaccine in December of 2025 and

additional vaccines in early January 2026, many more states have expanded this scope to include all childhood vaccines.

**The red-blue divide in vaccine policy continues with all blue states (those with Democratic governors) departing from federal guidelines...**

### **Trump Administration Drops Medicaid Vaccine Reporting Requirements**

Author: Elizabeth Williams

Published: Jan 9, 2026

In a letter to state health officials last month, the Centers for Medicare & Medicaid Services (CMS) announced the removal of immunization measures from the Child Core Set and Adult Core Set. These "Core Sets" measure health care performance annually, with the goal of improving the health of Medicaid and Children's Health Insurance Program (CHIP) enrollees. Dropping Medicaid vaccine reporting requirements may make it more challenging to monitor vaccination trends and the impact of recent vaccine policy changes. This policy watch describes the recent Trump administration changes to Medicaid vaccine reporting requirements and explores what impact this change may have on state Medicaid programs and enrollees.

The "Core Sets" are a set of quality measures designed to measure and improve health care quality and access. The Core Set of Children's Health Care Quality Measures for Medicaid and CHIP, or the "Child Core Set", includes quality measures that capture various aspects of children's health such as behavior health care, preventive care, maternal health, acute and chronic conditions, oral health care, and experience of care as well as vaccination status. The Child Core Set was developed in 2009, voluntary annual state reporting began in 2010, and reporting became mandatory in 2024. There is also a separate set of quality measures for adult enrollees, the "Adult Core Set". The Adult Core Set was developed in 2012, voluntary annual state reporting began in 2014, and the behavioral health measures became mandatory for states to report in 2024. To enforce compliance with mandatory measures, CMS has the authority to withhold federal Medicaid payments, though states can request a one-year exemption if they are unable to report for a specific population and measure. The Core Set data are made publicly available and are designed to measure health care access and quality for Medicaid/CHIP enrollees, allowing states to monitor health care quality, identify improvement opportunities, and address health disparities.

The Trump administration recently removed four immunization measures from the Core Sets, making them voluntary for states to report...

:::::::

### **Vaccine Integrity Project – CIDRAP [to 25 Jan 2026]**

<https://www.cidrap.umn.edu/vaccine-integrity-project>

*Announcements*

*No new digest content identified.*

:::::::

### **Paul Offit, MD – *Beyond the Noise***

Substack: <https://pauloffit.substack.com/>

*[Selected]*

### **RFK Jr.'s Strategy for Restoring Trust**

*Just make one false claim after the next and never look back. Never admit you were wrong. Never apologize.*

Jan 20, 2026

:::::::

## **Art Caplan, PhD, NYU**

*Perspectives*

*No new digest content identified.*

::::::

::::::

### ***Contents [click to move among sections]***

- [\*:: Milestones, Perspectives\*](#)
- [\*:: WHO\*](#)
- [\*:: Organization Announcements\*](#)
- [\*:: Journal Watch\*](#)
- [\*:: Pre-Print Servers\*](#)

::::::

::::::

## ***Organization Announcements***

### **Paul G. Allen Frontiers Group [25 Jan 2026]**

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

### **BMGF - Gates Foundation [25 Jan 2026]**

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*Press release Jan 22, 2026*

### **New Global Consortium Aims to Transform Antibiotic Discovery to Counter the Growing AMR Crisis**

*Philanthropic partners invest \$60M to support collaborative research to accelerate the discovery of next-generation antibiotics*

SEATTLE, COPENHAGEN, LONDON (January 22, 2026) – The Gates Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of \$60 million in new grant funding over the next three years to research teams around the world exploring novel approaches to antibiotic discovery to deal with the growing threat of antimicrobial resistance (AMR). The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) will function as a first-of-its-kind consortium where multiple funders and research teams openly share data and learnings and work collectively to accelerate the discovery of urgently needed antibiotics.

Eighteen projects led by research teams across 17 countries are receiving funding based on their potential to transform antibiotic discovery for Gram-negative bacteria, one of the leading drivers of AMR-related deaths worldwide. Gr-ADI is the first investment of the \$300 million global health research and development partnership launched by the Gates Foundation, Novo Nordisk Foundation, and Wellcome in 2024...

*Press release Jan 14, 2026*

### **Gates Foundation Commits to Historic \$9 Billion Annual Payout, Strengthens Stewardship to Maximize Mission Impact Through Closure in 2045**

*Foundation is planning operating expenditures at approximately 14% annually to ensure more funds are directed to the programs and people we serve*

SEATTLE (January 14, 2026) – The Gates Foundation today announced that its governing board endorsed a historic \$9 billion annual payout, marking a culmination of a four-year plan to reach a steady-state budget at this level. The increase in spending is part of the foundation's commitment to accelerate its mission ahead of its planned closure in 2045.

*Press release Jan 12, 2026*

**Gates Foundation Appoints New Members to Governing Board, Executive Leadership Team and Elevates Role of African and India Offices**

**CARB-X** [25 Jan 2026]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Chan Zuckerberg Initiative** [25 Jan 2026]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [25 Jan 2026]

<http://cepi.net/>

*CEPI News, Blog*

*News*

**CEPI backs updated Zaire ebolavirus vaccine that aims to improve vaccine affordability and accessibility**

\$30 million to update manufacturing process and make a vaccine intended to be less costly to produce and easier to deploy.

20 Jan 2026

*News*

**CEPI, Oxford, Serum create largest-ever reserve of investigational Rift Valley fever vaccine**

12 Jan 2026

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 25 Jan 2026]

<https://cioms.ch/>

*News; Publications; Events*

**Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION DRAFT REPORT**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences. Deadline to submit your comments is 13 March 2026.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [25 Jan 2026]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**DNDI – Drugs for Neglected Diseases initiative** [25 Jan 2026]

<https://dndi.org/press/press-releases/>

*Press Releases*

*No new digest content identified.*

**Duke Global Health Innovation Center** [25 Jan 2026]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [25 Jan 2026]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [25 Jan 2026]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [25 Jan 2026]

<http://www.euvaccine.eu/>

*News*

*No new digest content identified.*

**Fondation Merieux** [25 Jan 2026]

<http://www.fondation-merieux.org/>

*Actualités*

*No new digest content identified.*

**Gates Medical Research Institute** [25 Jan 2026]

<https://www.gatesmri.org/news>

*The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.*

*News: Articles and Publications*

*No new digest content identified.*

**Gavi** [to 25 Jan 2026]

<https://www.gavi.org/>

*News Releases*

22 January 2026

### **Gavi announces new partnerships to accelerate innovation and expand access to immunisation**

:: New private-sector and philanthropic partnerships will help Gavi scale innovation, strengthen healthcare and reach underserved communities

:: Public-private collaboration reinforcing Gavi's innovation model amid a changing global health landscape

:: "Gavi's public-private partnership model is more relevant than ever, helping countries scale proven health solutions through innovation, strong partnerships and the support of donors and governments," said Dr Sania Nishtar

21 January 2026

### **Gavi CEO calls for global health leap**

:: Gavi CEO Dr Sania Nishtar, writing in *The Lancet*, sets out a framework for radical reform of global health institutions

:: Global health institutions should merge operations in countries in order to focus on generating global public goods, scaling impact and supporting the most fragile contexts, Dr Nishtar writes

"" Dr Sania Nishtar: "We must move away from piecemeal reform and imagine a new system that places the needs of countries, not the institutions themselves, at its heart."

### **GE2P2 Global Foundation [25 Jan 2026]**

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements/Digests*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 12 Nov 2025](#)

:: [Genomics, Gene Editing, Convergent Biosciences: Governance, Ethics, Policy, Practice – A Monthly Review – Nov 2025](#)

### **GHIT Fund [25 Jan 2026]**

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

*No new digest content identified.*

### **Global Fund [to 25 Jan 2026]**

<https://www.theglobalfund.org/en/news/>

*News Releases*

21 January 2026

### **Johnson & Johnson Foundation, Skoll Foundation and Comic Relief UK Commit Nearly US\$15 Million to Strengthen Community Health Systems Across Africa**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced a £3 million commitment from Comic Relief UK to strengthen community health systems across Africa. This pledge builds on previously announced commitments of US\$5 ...

### **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [25 Jan 2026]**

<https://www.glopid-r.org/>

*News & Events*

*No new digest content identified.*

**Hilleman Laboratories** [25 Jan 2026]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [25 Jan 2026]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project** [nee Human Vaccines Project] [25 Jan 2026]

<https://www.humanimmunomeproject.org/>

*News*

*No new digest content identified.*

**IAVI** [25 Jan 2026]

<https://www.iavi.org/>

*Press Releases, Features*

*No new digest content identified.*

**INSERM** [25 Jan 2026]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

14 January 2026

**[ICMRA Statement on Regulators as communicators: strengthening regulatory communication for public health](#)**

... Regulators must be known, understood and trusted by those whose health they protect. This requires timely, clear and accurate information—delivered with empathy and targeted to the needs of diverse audiences.

As apolitical, science-based institutions, medicines regulators have a vital role in translating complex scientific data into accessible language for all. Across the Coalition, members have many successful examples of public engagement that support health measures and build trust.

ICMRA members will join together to strengthen global communication efforts to ensure the information they provide remains a cornerstone of public health protection in an increasingly complex world.

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 25 Jan 2026]**

<https://www.ich.org/>

*News/Pubs/Press Releases [Selected]*

23 January 2026

**Final ICH51 Management Committee and Assembly Meeting Minutes Now Available**

The minutes of the ICH Management Committee and ICH Assembly meetings held in Singapore at ICH51 have been published. These documents summarise the decisions taken and topics discussed during the face-to-face biannual meetings, which took place in November 2025.

15 January 2026

**Updated Technical Documents Issued by ICH Expert Working Groups for Three Guidelines**

Three ICH Expert Working Groups have issued an updated document package, a mapping document and training materials, respectively, associated with three technical Guidelines: E2B(R3) - Individual Case Safety Report Specification; M4Q(R2) - The Common Technical Document; and E6(R3) - Good Clinical Practice.

Ongoing Public Consultations ^

> [Q3E EWG Guideline for Extractables and Leachables](#)

> [E22 EWG General Considerations for Patient Preference Studies](#)

<https://www.ich.org/page/public-consultations>

**ICRC [to 25 Jan 2026]**

<https://www.icrc.org/en/news>

*Latest press releases and statements*

**Syria: ICRC concerned over worsening humanitarian situation**

21-01-2026

Syria (ICRC) - An alarming humanitarian crisis is brewing in northeast Syria, and civilians are once again paying the heaviest price. Renewed hostilities over the past few days have forced families—many already displaced multiple times—to flee in the depths of winter with little access to water, warmth, or healthcare, while also increasing the risk of family separation.

**IFFIm [25 Jan 2026]**

<http://www.iffim.org/>

*Press Releases/Announcements*

**IFRC [to 25 Jan 2026]**

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press releases*

*No new digest content identified.*

**IPPS - International Pandemic Preparedness Secretariat [25 Jan 2026]**

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [25 Jan 2026]  
<https://www.pasteur.fr/en/press-area>  
*Press Documents*  
*No new digest content identified.*

**ISC / International Science Council** [to 25 Jan 2026]  
<https://council.science/current/>  
*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*  
*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**  
<https://iuis.org/>  
*News, Resources*  
*No new digest content identified.*

**IVAC** [25 Jan 2026]  
<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>  
*Updates; Events*  
*No new digest content identified.*

**IVI** [25 Jan 2026]  
<http://www.ivi.int/>  
*IVI News & Announcements*  
[\*\*IVI and the Institute of Tropical Medicine in Antwerp sign Memorandum of Understanding to advance vaccine research and development for global health and equitable access to vaccines\*\*](#)  
29 December 2025

**Johns Hopkins Center for Health Security** [25 Jan 2026]  
<https://centerforhealthsecurity.org/newsroom>  
*Center News [Selected]*  
January 12, 2026:  
[\*\*New SHIELD Project to Modernize U.S. Preparedness Systems Through Innovation and Leadership\*\*](#)

**Robert Wood Johnson Foundation** [to 25 Jan 2026]  
<https://www.rwjf.org/en/about-rwjf/newsroom.html>  
*Latest News and Highlights*  
*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 25 Jan 2026]  
<http://www.msf.org/>  
*Latest [Selected Announcements]*

*Gaza-Israel war*

**MSF statement on staff registration and the continuation of medical care in the Occupied Palestinian Territory**

Statement 24 Jan 2026

*Attacks on medical care*

**Report: Medical care in the crosshairs**

Report 22 Jan 2026

*Attacks on medical care*

**Attacks on medical care in armed conflict reach record levels**

Press Release 22 Jan 2026

*United States of America*

**One year later: How US policies are reshaping global health and humanitarian aid**

Press Release 21 Jan 2026

*Gaza-Israel war*

**Addressing frequently asked questions and allegations about MSF's work in Gaza**

Project Update 16 Jan 2026

*South Sudan*

**Movement restrictions prevent people from accessing lifesaving medical care in Jonglei state**

Press Release 16 Jan 2026

**National Academy of Medicine** - USA [to 25 Jan 2026]

<https://nam.edu/programs/>

*News, Stories, Insights*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 25 Jan 2026]

<https://www.nationalacademies.org/newsroom>

*News*

**National Academies Respond to OSTP Request for Information on Accelerating the U.S. Research Enterprise**

Jan 20, 2026

Late last year, the White House Office of Science and Technology Policy issued a request for information (RFI) in the Federal Record on “priorities for strengthening the science and technology ecosystem to support both the expansion of scientific knowledge and the mechanisms to transition these discoveries into the marketplace.” OSTP said that the information submitted “will inform the formulation of Executive branch efforts to advance and maintain U.S. S&T leadership.”

The National Academies entered a response to the RFI that drew upon an extensive body of its recent work aimed at advancing U.S. science and innovation. “Across our work advising administrations of both parties; convening expertise and practice from science, engineering, and medicine; and synthesizing evidence to inform policy, we see a moment of structural change that calls for new approaches to discovery, translation, and talent development that can power economic growth and improve American lives,” said the presidents of the three Academies in a letter accompanying the response.

**PATH** [25 Jan 2026]  
<https://www.path.org/media-center/>  
*Newsroom [Selected]*  
*No new digest content identified.*

**Sabin Vaccine Institute** [25 Jan 2026]  
<https://www.sabin.org/press/>  
*Latest News & Press Releases*  
*No new digest content identified.*

**UNAIDS** [25 Jan 2026]  
<http://www.unaids.org/en>  
*News, Stories, Updates*  
*No new digest content identified.*

**UNICEF** [to 25 Jan 2026]  
<https://www.unicef.org/media/press-releases>  
*Latest press releases, news notes and statements [Selected]*  
*Remarks 20 January 2026*  
**In Mozambique, heavy floods are turning unsafe water and malnutrition into a deadly threat for children**

XAI XAI/GENEVA, 20 January 2026 –, "In Mozambique today, flooding is not just destroying homes, schools, health centres and roads. It is turning unsafe water, disease outbreaks and malnutrition into a deadly threat for children. "The exceptionally heavy rains that we've seen during the first weeks of January hav...

**Unitaid** [25 Jan 2026]  
<https://unitaid.org/>  
*News releases*  
**New report highlights innovative solutions to strengthen access to quality life-saving maternal and newborn health products**  
23 January 2026

**Vaccine Equity Cooperative [nee Initiative]** [25 Jan 2026]  
<https://vaccineequitycooperative.org/news/>  
*News*  
*No new digest content identified.*

**Vaccine Confidence Project** [25 Jan 2026]  
<http://www.vaccineconfidence.org/>  
*News, Research and Reports*  
*No new digest content identified.*

**Vaccine Education Center – Children's Hospital of Philadelphia** [25 Jan 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [25 Jan 2026]

<https://wellcome.org/news/all>

*News, Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 25 Jan 2026]

<https://www.wistar.org/news/press-releases>

*Press Releases*

January 13, 2026

**[The Wistar Institute Announces the Recruitment of Jianliang Xu, Ph.D., to the HIV Cure and Viral Diseases Center](#)**

Xu specializes in antibody research & engineers nanobodies—tiny, effective tools against HIV & emerging pandemics

**World Bank** [to 25 Jan 2026]

<http://www.worldbank.org/en/news/all>

*News [Selected]*

**[Stronger Primary Health Care Can Boost Growth and Create Jobs across East Asia and Pacific](#)**

WASHINGTON, DC, January 21, 2026 — East Asia and Pacific (EAP) is at a crossroads, as a surge of chronic, noncommunicable diseases (NCDs) threatens to overwhelm health systems and stall income growth...

Date: January 21, 2026 Type: Press Release

**WFPHA: World Federation of Public Health Associations** [25 Jan 2026]

<https://www.wfpha.org/>

*Blog, Events*

**[Statement on the Global Public Health Crisis of Military Aggression: In Defense of Health, Peace, and Democracy](#)**

Jan 19, 2026 | *News*

Statement on the Global Public Health Crisis of Military Aggression: In Defense of Health, Peace, and Democracy The World Federation of Public Health Associations (WFPHA) expresses its profound alarm and unequivocal condemnation of the escalating pattern of unilateral military aggressions by the United States government.

**World Medical Association [WMA]** [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

**[WMA Condemns Violence Against Medical Personnel in Syria](#)**

21.01.2026

**[World Medical Association Appeals for Rapid and Unobstructed Delivery of Emergency Aid in Gaza](#)**

15.01.2026

**World Organisation for Animal Health [OIE] [25 Jan 2026]**

<https://www.oie.int/>

*Press Releases, Statements*

*Statement*

**Statement on Animal Welfare during transport**

Published on 19 January 2026

The World Organisation for Animal Health (WOAH) reiterates with renewed sense of urgency that while transporting animals—by land, sea, or air—can be a key for global trade, food production, research, and others, it is critical to ensure the rigorous implementation of welfare standards throughout their transport process to safeguard animal health and well-being.

Long-distance transport can represent serious risks due to—missing or incomplete health certificates, unclear customs rules, commercial disagreements, and unexpected problems. These issues must be carefully planned for and managed from the start to protect animal welfare...

:::::

::::::

**ARM [Alliance for Regenerative Medicine] [25 Jan 2026]**

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest announcements identified.*

**BIO [25 Jan 2026]**

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest announcements identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network [25 Jan 2026]**

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest announcements identified.*

**ICBA – International Council of Biotechnology Associations [25 Jan 2026]**

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA [25 Jan 2026]**

<https://ifpma.org/>

*News & Resources*

*No new digest announcements identified.*

**International Alliance of Patients' Organizations – IAPO [25 Jan 2026]**

<https://www.iapo.org.uk/news>

*Press and media [Selected]  
No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [25 Jan 2026]

<http://www.phrma.org/>

*Press Releases*

January 15, 2026

**PhRMA Statement on the White House's Great Healthcare Plan Announcement**

::::::

::::::

**Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements**

*We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.*

**AstraZeneca**

Press Releases - *No new digest announcements identified.*

**Bavarian Nordic**

Latest News

**Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil**

:: Agreement to enable the first entry in Latin America for Bavarian Nordic's chikungunya vaccine

:: Potential to expand agreement to cover rest of Latin America

COPENHAGEN, Denmark, January 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic's chikungunya vaccine, CHIKV VLP, in Brazil. Eurofarma is also granted the right of first refusal for any future opportunity to register and commercialize the chikungunya vaccine in the rest of Latin America...

**BioCubaFarma – Cuba**

Últimas Noticias - *No new digest announcements identified.*

**Biological E**

News - *No new digest announcements identified.*

**BioNTech**

Press Releases - *No new digest announcements identified.*

**Boehringer**

Press Releases - *No new digest announcements identified.*

**CanSinoBIO**

News - *Website not responding at inquiry.*

**CIGB**

Latest News - No new digest announcements identified.

**CinnaGen**

Recent News - Website not responding at inquiry

**Clover Biopharmaceuticals – China**

News

Jan 11, 2026\

[\*\*Clover Initiates Phase 2 Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates\*\*](#)

**CSL Sequirus**

News Releases - No new digest announcements identified.

**Curevac**

News - Website now directs to BioNTech site

**Daiichi Sankyo**

Press Releases

January 22, 2026

Corporate

[\*\*Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe\(153.9KB\)\*\*](#)

**Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

**GSK**

Press releases for media - No new digest announcements identified.

**EuBiologics, S Korea**

News - No new digest announcements identified.

**HIPRA**

Press releases

[\*\*HIPRA and Elanco partner to introduce two avian metapneumovirus \(aMPV\) vaccines to the U.S.\*\*](#)

20-01-2026

HIPRA and Elanco Animal Health have partnered to bring two avian metapneumovirus (aMPV) vaccines to the U.S. poultry market, providing new tools for producers to manage this costly respiratory disease.

**IMBCAMS, China**

Home - Website not responding at inquiry.

**JNJ Innovative Medicine [Janssen]**

Press Releases - No new digest announcements identified.

**Merck**

News releases - No new digest announcements identified.

**Nanogen**

News - No new digest announcements identified.

**Novartis**

News - No new digest announcements identified.

**Novavax**

Press Releases

**Novavax Announces Entering into a License Agreement with Pfizer**

January 20, 2026

- :: Non-exclusive license allows for development by Pfizer to utilize Matrix-M® for up to two disease areas with its products
- :: Provides Novavax with an upfront payment of \$30 million with the potential for up to another \$500 million in development and sales milestones. In addition to milestone payments, Novavax is eligible to receive high mid-single digit percentage royalties

**Pfizer**

Recent Press Releases - No new digest announcements identified.

**R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

**Sanofi Pasteur**

Press Releases - No new digest announcements identified.

**Serum Institute**

News & Announcements

**Oxford University enters into licensing arrangement with SII to develop Rift Valley fever vaccine candidate.**

Tuesday, January 13, 2026

- :: Serum Institute of India to make up to 100,000 investigational Oxford Rift Valley fever vaccine doses.
- :: Rift Valley fever is a potentially deadly viral disease currently affecting West Africa.
- :: Doses manufactured by Serum Institute of India could be set aside for testing to combat the outbreak and future Rift Valley fever emergencies.
- :: The epidemic preparedness organisation CEPI helped spearhead the agreement.

**Sinopharm/WIBPBIBP**

News - No new digest announcements identified.

**Sinovac**

Press Releases - No new digest announcements identified.

**SK Biosciences**

Press Releases

**SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding**

2026.01.22

- :: CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine

- :: Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability
- :: Partnership aims to expand affordable and sustainable vaccine access in low- and middle-income countries

## **[SK bioscience Marks the Start of Its "Songdo Era" Global R&PD Center Begins Operations as a New Global Innovation Hub](#)**

2026.01.19

### **Takeda**

*[Newsroom](#) - No new digest announcements identified.*

### **Valneva**

*[Press Releases](#)*

January 19, 2026

#### **[Valneva Provides Update on Chikungunya Vaccine IXCHIQ®](#)**

- :: Company voluntarily withdraws IXCHIQ BLA and IND in the U.S.
- :: Continuing review of global product opportunity according to medical need and commercial attractiveness

### **WestVac Biopharma**

*[Media](#) - No new digest announcements identified.*

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*[Website](#) [No News/Announcements page identified]*

::::::

::::::

### ***Contents [click to move among sections]***

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)

::::::

::::::

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/electronic-health-record-evolution>

#### **Aging Is Bad for You?**

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

### **American Journal of Human Genetics**

Jan 08, 2026 Volume 113 Issue 1 p1-234

<https://www.cell.com/ajhg/current>

[New issue: no digest content identified]

### **American Journal of Infection Control**

December 2025 Volume 53 Issue 12 p1243-1366

<http://www.ajicjournal.org/current>

*Monthly Spotlight*

#### **Vaccine ambassadors: An educational model to empower youth and spread awareness of vaccines in Detroit**

Jennifer Schmidt, et al.

Published in issue: January 2026

### **American Journal of Preventive Medicine**

February 2026 Volume 70 Issue 2

<https://www.ajpmonline.org/current>

[New issue: no digest content identified]

### **American Journal of Public Health**

January 2026 116(1)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 113 (2025): Issue 6 (Dec 2025)

<https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-6.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

January 2026 Volume 179, Issue 1

<https://www.acpjournals.org/toc/aim/current>

*Clinical Guidelines*

**[Influenza Vaccines for 2025–2026 in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians](#)**

Amir Qaseem, MD, PhD, MHA, Timothy J. Wilt, MD, MPH, Curtis S. Harrod, PhD, MPH, Adam J. Obley, MD, ... et al.

Pages:110–117

**Artificial Intelligence – An International Journal**

Volume 349 December 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/349/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 25 Jan 2026)

**[Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective](#)**

Diana Mendes, Ahuva Averin, Jeffrey Vietri

Research Open access 21 January 2026

**BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 25 Jan 2026)

[No new digest content identified]

**BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 25 Jan 2026)

**[Factors influencing influenza vaccine hesitancy among cancer patients: a multicenter cross-sectional study based on the Health Belief Model](#)**

Qinghua Dong, Yiwei Luo, Hui Ma

Research Open access 24 January 2026

**[The impacts of COVID-19 on routine immunization for children in Rwanda](#)**

Edward Mbonigaba, Fengyun Yu, Simiao Chen

Research Open access 24 January 2026

**[Adherence to hepatitis B vaccination recommendations for children and adolescents aged 3 to 17 years in Germany, 2014–2017: results from a cross-sectional national population-based study](#)**

Sofie Gillesberg Lassen, Thomas Harder, Christina Poethko-Müller

Research Open access 16 January 2026

**[Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease](#)**

Charlot Diepvens, Donovan Guttieres, Catherine Decouttere  
Research Open access 10 January 2026

**BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 25 Jan 2026)

**[War, ethics, and market presence: policy shifts of global pharmaceutical companies in Russia following the 2022 invasion of Ukraine](#)**

Daniel J. Hurst, Krisha Darji, Christopher A. Bobier  
Research Open access 17 January 2026

**[Adapting research ethics for global health crises: a systematic analysis of COVID-19 pandemic research guidelines and reflections on their post-pandemic implications](#)**

Vilma Lukaševičienė, Eugenijus Gefenas  
Research Open access 10 January 2026

**[Exploring moral distress in research students in a paediatric humanitarian research setting: a qualitative study from the Mavrovouni closed controlled access center, Lesvos, Greece](#)**

Hanaâ Benjeddi, Mariana Dittborn, Joe Brierley  
Research Open access 09 January 2026

**BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 25 Jan 2026)

**[Pay-it-forward intervention increased pneumococcal vaccine uptake among older adults in China: a randomized controlled trial](#)**

Jiao Qin, Chunxing Tao, Bingyu Liang  
Research Open access 19 January 2026

**BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 25 Jan 2026)

**[Influenza vaccination coverage among pregnant women during the 2023–2024 influenza season in Turkiye, a cross sectional study](#)**

Fatma Guven, Burcu Ecem Uguz, Tayyar Sasmaz  
Research Open access 20 January 2026

**BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 25 Jan 2026)

*Articles*

**[Overcoming barriers to vaccination among U.S. farmworkers: a scoping review of targeted interventions and strategies](#)**

Roldyne Dolce, Rachel Barnes, Paula M. Cuccaro  
Systematic Review Open access 24 January 2026

**Determinants of vaccination willingness among people experiencing homelessness: a cross-sectional study in Warsaw, Poland**

Zuzanna Matuszewska, Paulina Maria Szot, Katarzyna Lewtak  
Research Open access 21 January 2026

**Economic evidence for expansion of HPV vaccination for the prevention of cervical cancer in LMICs: BIA framework construction and empirical analysis in China**

Yi Li, Ran Xin, Xin Zhang  
Research Open access 19 January 2026

**Views on HPV-vaccination held by parents of Turkish and Moroccan origin in the Netherlands: an exploratory study using Q-methodology**

Enise Çayci, Thijs van den Broek, Anna P. Nieboer  
Research Open access 17 January 2026

**Understanding perceptions towards COVID-19 vaccination and strategies to increase vaccine uptake among Ebola- affected communities in North Kivu, Democratic Republic of the Congo: a qualitative study**

Eta Ngole Mbong, Shiromi M. Perera, Rigobert Fraterne Muhayangabo  
Research Open access 13 January 2026

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>  
(Accessed 25 Jan 2026)  
[No new digest content identified]

**BMJ Evidence-Based Medicine**

December 2025 - Volume 30 - 6  
<https://ebm.bmj.com/content/30/6>  
[Reviewed earlier]

**BMJ Global Health**

January 2026 - Volume 11 - 1  
<https://gh.bmj.com/content/11/1>  
*Original research*

**Characterising concerns and misinformation shaping global HIV vaccine confidence and demand: a structured literature search and content analysis** (8 January, 2026)

Simamkele Bokolo, Megan Rabin, Sarah Penuela-Wermers, Candice Maylene Chetty-Makkan, Teniola I Egbe, Harsha Thirumurthy, Brendan Maughan-Brown, Alison Buttenheim

**Public preferences and decision-making for mpox vaccination in the African region: a multinational discrete choice experiment** (6 January, 2026)

Min Du, Jie Deng, Wenxin Yan, Shimo Zhang, Shunzhe Wu, Min Liu, Wannian Liang, Jue Liu

**Bulletin of the Atomic Scientists**

DIGITAL MAGAZINE - December 2025  
<https://thebulletin.org/magazine/2025-12/#post-heading>

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 104, Number 1, January 2026, 1-60

#### **Effective care for mothers and their babies during humanitarian crises.**

Cocoman O, Tappis H, Scudder E, Ruyzen H, Patterson JM, Prabhu SM, Kitamura T, Fair M, Abdullah M, Siddeeg K, Afifi M, Kayita J, Khumbizeni SC, Zombre Sanon VM, Abgren KA, Chaya R, Rammal T, El Nour M, Mitchell K, Schulte-Hillen C, Gupta G, Moran A.

Bull World Health Organ. 2026 Jan 1;104(1):2-3. doi: 10.2471/BLT.25.295391.

PMCID: PMC12706716

### **Cell**

Jan 22, 2026 Volume 189 Issue 2 p343-696

<https://www.cell.com/cell/current>

#### *Commentary*

#### **A two-tier framework for responsible research on human embryo models**

Alejandro De Los Angeles, et al.

Human stem-cell-based embryo models (SCBEMs) imperfectly mimic some—but not all—features of early human development. We propose a two-tiered oversight structure anchored in a single fixed ethical principle: no SCBEM should ever attain the capacity for sentience (the ability to experience sensory inputs, such as pain).

### **Cell and Gene Therapy Insights**

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

### **Child Care, Health and Development**

Volume 52, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 118, Issue 6 Pages: 1225-1567 December 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

January 2026 Volume 48 Issue 1 p1-134

<http://www.clinicaltherapeutics.com/current>

#### *Reviews*

#### **Efficacy and safety of Monoclonal Antibodies in Malaria Protection and Prevention of Transmission: A Systematic Review**

Kanika Verma, et al.

Published online: December 13, 2025

p104-116

**Clinical Trials**

Volume 22 Issue 6, December 2025

<https://journals.sagepub.com/toc/ctja/22/6>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 25 Jan 2026]

**[Vaccine hurdles for children in war-torn Somalia: the result of post-campaign coverage survey 2025](#)**

Abdulwahab M. Salad, Mohamed A. Gedi, Abdi Gele

Research Open access 20 January 2026

**Contemporary Clinical Trials**

Volume 159 December 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/159/suppl/C>

[Reviewed earlier]

**The CRISPR Journal**

Volume 8, Issue 6 / December 2025

<https://www.liebertpub.com/toc/crispr/8/6>

[Reviewed earlier]

**Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

**Current Medical Research and Opinion**

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

**Current Opinion in Infectious Diseases**

October 2025 - Volume 38 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*PAEDIATRIC AND NEONATAL INFECTIONS*

[Reviewed earlier]

**Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 25 Jan 2026]

[No new digest content identified]

**Cytotherapy**

March 2026 Volume 28 Issue 3

<https://www.isct-cytotherapy.org/current>

[New issue. No digest content identified]

**Developing World Bioethics**

Volume 25, Issue 4 Pages: 253-323 December 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

**Development in Practice**

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

**Development Policy Review**

Volume 44, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

**Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

**Disasters**

Volume 50, Issue 1 January 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

**eBioMedicine**

Volume 122 December 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/121/suppl/C>

[Reviewed earlier]

**EMBO Reports**

Volume 27, Issue 1 January 2026

<https://www.embopress.org/toc/14693178/current>

**Equitable Open Access**

Bernd Pulverer

Editorial Open access 08 December 2025 Pages: 1 - 2

### **An evaluation system for scientific journals**

Diethard Tautz, Paul B Rainey  
Opinion Open access 08 December 2025 Pages: 3 - 4

### **The geopolitical turn in biotechnology**

Ruth Mampuys, Haroon Sheikh  
Science & Society Open access 04 December 2025 Pages: 5 - 9

### **A global effort toward standards for data sharing in biomedical imaging**

Sophie L Winter, Josh Moore, Linda Chaabane  
Science & Society Open access 03 December 2025 Pages: 10 - 14

### **Emerging Infectious Diseases**

Volume 31, Number 11—November 2025  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 53 December 2025  
<https://www.sciencedirect.com/journal/epidemics/vol/53/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 153 - 2025  
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 48, Issue 1 Pages: 1-48 January–February 2026  
<https://onlinelibrary.wiley.com/toc/25782363/current>

#### ***Research and pregnant women • Considerations for informed consent***

Articles

#### **Policies for the Inclusion of Pregnant Women in Research: Results from an International and a US Study**

Anne Drapkin Lyerly, Renee Muthakana, Aliyah Webster, Jason Lee, Stephanie Moss, Madeleine Fairey, Allyson Riddle, Min Shi, David B. Resnik  
Pages: 2-11  
First Published: 31 December 2025

#### **Mandating Evidence-Based Informed Consent Practices: A Critical Engagement with IRB Leader Focus Group Findings**

Meredith V. Parsons, Erin D. Solomon, Kari Baldwin, Jessica Mozersky, James M. DuBois  
Pages: 12-27  
First Published: 31 December 2025

### **Ethics & International Affairs**

Volume 39 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [  
[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>  
[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 6, December 2025

<https://academic.oup.com/eurpub/issue/35/6>

*Socioeconomic Factors*

#### **[Sociodemographic factors influencing childhood vaccination in Albania: a cross-sectional study](#)**

Ledia Qatipi and others

*European Journal of Public Health*, Volume 35, Issue 6, December 2025, Pages 1115–1121,  
<https://doi.org/10.1093/eurpub/ckaf151>

#### **[National identification and trust in institutions: understanding lower COVID-19 vaccination uptake among ethnic minorities in Europe](#)**

Aoife-Marie Foran and others

*European Journal of Public Health*, Volume 35, Issue 6, December 2025, Pages 1314–1319,  
<https://doi.org/10.1093/eurpub/ckaf206>

### **Expert Review of Vaccines**

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

*Review Article*

#### **[Pneumococcal conjugate vaccines in older adults and immunocompromised individuals](#)**

Viravarn Luvira, Thundon Ngamprasertchai & Punnee Pitisuttithum

Article: 2602525

Published online: 12 Dec 2025

*Review Article*

#### **[Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review](#)**

Valeria Gabellone, Fabiana Nuccetelli, Elisa Gabrielli, Rosa Prato & Pierluigi Lopalco

Article: 2607479

Published online: 25 Dec 2025

*Review Article*

#### **[Global status of HPV vaccination two decades in: effective, safe and preventing cancer](#)**

Julia M. L. Brotherton, D. Scott LaMontagne & Paul J. N. Bloem

Article: 2609869

Published online: 30 Dec 2025

### **Foreign Affairs**

January/February 2026 Volume 105, Number 1

<https://www.foreignaffairs.com/issues/2026/105/1>

*Essays*

**The Weakness of the Strongmen**

*What Really Threatens Authoritarians?*

Stephen Kotkin

**The Price of American Authoritarianism**

*What Can Reverse Democratic Decline?*

Steven Levitsky, Lucan A. Way, and Daniel Ziblatt

**The Illiberal International**

*Authoritarian Cooperation Is Reshaping the Global Order*

Nic Cheeseman, Matías Bianchi, and Jennifer Cyr

**Forum for Development Studies**

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

***The Rebirth of the Global South: Geopolitics, Imaginaries, and Developmental Realities***

[Reviewed earlier]

**Frontiers in Genetics**

<https://www.frontiersin.org/journals/genetics>

[Accessed 25 Jan 2026]

[No new digest content identified]

**Frontiers in Genome Editing**

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 25 Jan 2026]

*Mini Review*

Published on 16 Dec 2025

**Therapeutic applications of CRISPR-Cas9 gene editing**

Aditya Bharti, Joann Mudge

**Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 25 Jan 2026]

[No new digest content identified]

**Gene Therapy – Nature**

Volume 32 Issue 6, December 2025

<https://www.nature.com/gt/volumes/32/issues/6>

[New issue; No digest content identified]

**Genetics in Medicines**

Volume 27, Issue 12 December 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>  
[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>  
[Accessed 25 Jan 2026]  
[No new digest content identified]

### **Global Health Action**

Volume 18, Issue 1 (2025)  
<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>  
[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

December 2025 | Volume 13 | Number 2  
<http://www.ghspjournal.org/content/current>  
[New issue; No digest content identified]

### **Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+aw+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+aw+library+of+congress%29&sb=date_desc)  
[Accessed 25 Jan 2026]  
[No new digest content identified]

### **Global Public Health**

Volume 20, Issue 1 (2025)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 25 Jan 2026]  
[\*\*From ground realities to policy: a framework for assessing multipolar health system governance in conflict-affected and high-risk areas\*\*](#)  
Munzer Alkhalil, Zedoun Alzoubi, Sameen Siddiqi  
Research Open access 24 January 2026

### [\*\*China's global health diplomacy through the World Health Organization: a qualitative study\*\*](#)

Zhida Shang, Yanzhong Huang  
Research Open access 24 January 2026

### [\*\*Globalization and health in an emerging new world order\*\*](#)

Ronald Labonté, Deborah Gleeson, Remco van de Pas  
Editorial Open access 07 January 2026 Article: 4

## **Health and Human Rights**

Volume 27, Issue 2, December 2025

<https://www.hhrjournal.org/volume-27-issue-2-december-2025/>

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 20 - Issue 4 - October 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 10, November 2025

<https://academic.oup.com/heapol/issue/40/10>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Human Gene Therapy**

Volume 36, Issue 23-24 / December 2025

[https://www.liebertpub.com/toc/hum/36/2\\_3-24](https://www.liebertpub.com/toc/hum/36/2_3-24)

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

[Accessed 25 Jan 2026]

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

[Reviewed earlier]

## **Immunity**

Jan 13, 2026 Volume 59 Issue 1 p1-228

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 25 Jan 2026]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjurnal.com/content>

[Accessed 25 Jan 2026]

[No new digest content identified]

**International Health**

Volume 17, Issue 6, November 2025

<https://academic.oup.com/inthealth/issue/17/6>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol. 12 No. 12 (2025): December 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/131>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 54, Issue 5, October 2025

<https://academic.oup.com/ije/issue/54/5>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 18, Issue 5 4 November 2025

<https://www.emerald.com/ijhrh/issue/18/5>

[Reviewed earlier]

**JAMA**

January 20, 2026, Vol 335, No. 3, Pages 197-288

<https://jamanetwork.com/journals/jama/currentissue>

**Navigating Conflicting Vaccination Recommendations - Guidance for Clinicians**

Published Online: January 13, 2026 doi: 10.1001/jama.2026.0276

January 13, 2026

Michelle M. Mello, JD, PhD, MPhil; Rochelle P. Walensky, MD, MPH; Michael T. Osterholm, PhD, MPH;

Troyen A. Brennan, MD, MPH, JD

*free access*

*JAMA*. Published online January 13, 2026. doi:10.1001/jama.2026.0276

This Perspective discusses how clinicians can navigate conflicting vaccination recommendations following revisions from the Advisory Committee on Immunization Practices and US Centers for Disease Control and Prevention.

*[Excerpt]*

...in early January 2026, the administration took another destabilizing action without any ACIP meeting, public discussion, or consultation with career experts at the CDC.<sup>5</sup> Two HHS officials urged the CDC to remove multiple vaccines from the routine pediatric recommendations: hepatitis A and B, meningococcus, rotavirus, respiratory syncytial virus, influenza, and COVID-19.<sup>6</sup> The evidence "assessment" they offered as justification focused heavily on issues of public trust and what other countries require—not the "scientific, evidence-based, data-driven" analysis it promised.<sup>6</sup> Nevertheless, the recommendation was swiftly adopted by the CDC.<sup>7</sup>

These dramatic shifts in both the substance and process of vaccine policy leave clinicians caught between CDC recommendations and conflicting guidance from medical, public health, and other organizations, raising several pressing questions about legal liability and insurance coverage.<sup>8,9</sup>

*[Excerpt]*

*...The Outlook*

The recent moves by ACIP and the CDC have sowed confusion, fear, and uncertainty among physicians and the public.<sup>10</sup> The chaos may be part of the strategy for reducing childhood vaccine access. However, changes to the vaccines recommended by ACIP and the CDC need not, and should not, substantially affect clinical practice. So long as specialty societies and other authoritative organizations maintain independent, science-based recommendations, clinician liability risk should remain low and private insurance coverage should continue. More concerning is the prospect of restrictions on payment by Medicare, Medicaid, and the VFC program, although that appears stable for now. Going forward, clinicians should stay abreast of payment changes but feel confident in continuing to recommend and administer vaccines in accordance with unwavering professional consensus.

## **JAMA Health Forum**

January 2026, Vol 7, No. 1

<https://jamanetwork.com/journals/jama-health-forum/issue>

*Special Communication*

### **[Ten Core Concepts for Ensuring Data Equity in Public Health](#)**

Yiran Wang, PhD; Alicia E. Boyd, PhD; Lillian Rountree, MS; et al.

*JAMA Health Forum*. 2026;7(1):e256031. doi:10.1001/jamahealthforum.2025.6031

This Special Communication introduces a cross-disciplinary framework to integrate computer science principles with public health to address data inequities and ensure that digital and technological advances improve health outcomes for all.

*Editorial*

### **[In Search of Pharmaceutical Policy Innovation in the US](#)**

Sandro Galea, MD, DrPH; Julie Donohue, PhD

## **JAMA Pediatrics**

January 2026, Vol 180, No. 1, Pages 3-120

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

### **[Safeguarding Science—The Time Is Now](#)**

Elizabeth L. Cope, PhD, MPH; Aaron E. Carroll, MD, MS

*JAMA Pediatr*. 2026;180(1):9-10. doi:10.1001/jamapediatrics.2025.4627

This Viewpoint describes how recent US political actions are undermining science, identifies vulnerabilities of the scientific enterprise, and emphasizes the urgency of taking action to safeguard science.

### **State Repeal of Nonmedical Vaccine Exemptions and Kindergarten Vaccination Rates**

Anthony Bald, PhD; Samantha Gold, BS; Y. Tony Yang, ScD, LLM, MPH  
*JAMA Pediatr.* 2026;180(1):56-63. doi:10.1001/jamapediatrics.2025.4185

This cross-sectional study evaluates changes in kindergarten vaccination rates before and after US states repealed nonmedical vaccine exemptions.

### **JBI Evidence Synthesis**

January 2026 - Volume 24 - Issue 1  
<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>  
[New issue: No digest content identified]

### **Journal of Adolescent Health**

February 2026 Volume 78 Issue 2 p203-370  
<https://www.jahonline.org/current>

### **Philadelphia's Adolescent Vaccine Self-Consent Regulation: Provider Perspectives, Implementation Barriers, and Implications for Practice**

Marva M. Schödel, Gregory D. Zimet, Erika R. Cheng, Mary A. Ott  
Published online: November 20, 2025  
p315-321

### **Journal of Artificial Intelligence Research**

Vol. 83 (2025)  
<https://www.jair.org/index.php/jair>  
[Reviewed earlier]

### **Journal of Bioethical Inquiry**

Volume 22, Issue 3 September 2025  
<https://link.springer.com/journal/11673/volumes-and-issues/22-3>  
[Reviewed earlier]

### **Journal of Community Health**

Volume 50, Issue 6 December 2025  
<https://link.springer.com/journal/10900/volumes-and-issues/50-6>  
[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*  
Vol. 8 No. 01 (2025)  
<https://www.cmro.in/index.php/jcmro/issue/view/91>  
[Reviewed earlier]

**Journal of Development Economics**

Volume 178 January 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/178/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 20 Issue 5, December 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

November 2025 - Volume 79 - 11

<https://jech.bmjjournals.org/content/79/11>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 3 September 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 4, November 2025

<https://muse.jhu.edu/journal/55986>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 5 October 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 4 (2025)

<http://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of International Development**

Volume 38, Issue 1 Pages: 1-191 January 2026  
<https://onlinelibrary.wiley.com/toc/10991328/current>  
[New issue: No digest content identified]

**Journal of Law, Medicine & Ethics**

Volume 53 - Issue 3 - Fall 2025  
<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>  
**Public Health, Markets, and Law**  
[Reviewed earlier]

**Journal of Medical Ethics**

December 2025 - Volume 51 - 12  
<http://jme.bmjjournals.org/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 12, Issue 3 (2025)  
<https://institutionalrepository.aah.org/jpcrr/>  
[Reviewed earlier]

**The Journal of Pediatrics**

Volume 286 November 2025  
<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/286/suppl/C>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1  
<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>  
[Reviewed earlier]

**Journal of Public Health Management & Practice**

November/December 2025 - Volume 31 - Issue 6  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 46, Issue 4 December 2025  
<https://link.springer.com/journal/41271/volumes-and-issues/46-4>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

Volume 22, Issue 233 1 December 2025  
<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

**Journal of Travel Medicine**

Volume 32, Issue 8, December 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 99 • Number 10 • October 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Jan 24, 2026 Volume 407 Number 10526 p309-468

<https://www.thelancet.com/journals/lancet/issue/current>

*Editorial*

**[Advancing health care: the engine of India's ambitions](#)**

The Lancet

*Articles*

**[Profiling vaccine attitudes and subsequent uptake in 1·1 million people in England: a nationwide cohort study](#)**

Matthew Whitaker, et al.

*The Lancet Commissions*

**[The Lancet Commission on a citizen-centred health system for India](#)**

Vikram Patel, et al.

**The Lancet Child & Adolescent Health**

Dec 2025 Volume 9 Number 12 p817-890, e24-e27

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Oct 2025 Volume 7 Number 10

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Dec 2025 Volume 13 Number 12 e1991-e2179

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Nov 2025 Volume 25 Number 11 p1159-1264, e621-e675

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Dec 2025 Volume 10 Number 12 e1006-e1085

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

### **Lancet Respiratory Medicine**

Dec 2025 Volume 13 Number 12 p1041-1118, e59-e63

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>

[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 46 Issue 1, January 2026

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue S1 Pages: 1-462 November 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

***Special Issue: Mental Health and Substance Use Challenges Facing the United States:***

***What Can State Policy Makers Do***

[New issue; No digest content identified]

### **Molecular Therapy**

Jan 07, 2026 Volume 34 Issue 1 p1-644

<https://www.cell.com/molecular-therapy/current>

*Editorial*

**[Response to the FDA's proposed pathway for individualized genetic therapies](#)**

Timothy W. Yu, Janet Woodcock, et al.

The Food and Drug Administration (FDA) recently proposed a dedicated regulatory pathway for “personalized” therapies<sup>1</sup> targeting genetic variation found in small numbers of individuals. This pathway is important, timely, and urgently needed. A number of such interventions have been investigated—e.g., milasen, a customized antisense oligonucleotide (ASO) drug designed for a child with Batten disease<sup>2</sup> that led to a series of individualized therapies for serious, ultra-rare neurogenetic diseases,<sup>3</sup> and k-abe, a customized base editing therapy designed for an infant with CPS1 deficiency<sup>4</sup>—but no scalable or sustainable path for development has existed beyond research use supported by philanthropic or grant funding<sup>5</sup>.

## **Nature**

Volume 649 Issue 8098, 22 January 2026

<https://www.nature.com/nature/volumes/649/issues/8098>

### ***Lost science***

It is one year since Donald Trump began his second term as president of the United States and, with grant cuts and staff reductions, these 12 months have seen some seismic changes in US science. In this week's issue, *Nature* examines how the US research landscape has changed — and what that means for the future. Elsewhere, leading biomedical researchers reflect on the events of 2025, and US scientists discuss how research careers are being forced to adjust. The cover image is derived from a treemap — rendered in glass and then shattered — that visualizes more

*Editorial* 15 Jan 2026

### **Making progress on global health will need high-quality evidence**

Nature Health, the newest journal in the *Nature* Portfolio, aims to bridge the 'implementation gap' from research to policy and practice.

*Comment* 20 Jan 2026

### **Trump one year on: How six US researchers plan to protect science amid chaos and cuts**

From education to pandemic preparedness and public health, the past year has seen huge stress put on US science.

Amander Clark, Hank Greely, Ramanan Laxminarayan

## **Nature Biotechnology**

Volume 43 Issue 12, December 2025

<https://www.nature.com/nbt/volumes/43/Issues/12>

[New issue; No digest content identified]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 25 Jan 2026)

[Reviewed earlier]

## **Nature Genetics**

Volume 57 Issue 12, December 2025

<https://www.nature.com/ng/volumes/57/Issues/12>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 9 Issue 10, October 2025

<https://www.nature.com/nathumbehav/volumes/9/Issues/10>

[Reviewed earlier]

## **Nature Medicine**

Volume 31 Issue 12, December 2025

<https://www.nature.com/nm/volumes/31/Issues/12>

[Reviewed earlier]

**Nature Reviews Drug Discovery**

Volume 24 Issue 12, December 2025

<https://www.nature.com/nrd/volumes/24/issues/12>

[Reviewed earlier]

**Nature Reviews Genetics**

Volume 26 Issue 12, December 2025

<https://www.nature.com/nrg/volumes/26/issues/12>

[Reviewed earlier]

**Nature Reviews Immunology**

Volume 25 Issue 12, December 2025

<https://www.nature.com/nri/volumes/25/issues/12>

[Reviewed earlier]

**New England Journal of Medicine Volume**

Volume 394 No. 4 January 22, 2026

<https://www.nejm.org/toc/nejm/medical-journal>

[No new digest content identified]

**NEJM Evidence**

Volume 4 No. 12 December 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[Reviewed earlier]

**npj Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 25 Jan 2026]

[No new digest content identified]

**Pediatrics**

Volume 156, Issue 6 December 2025

<https://publications.aap.org/pediatrics/issue/156/6>

[Reviewed earlier]

**PharmacoEconomics**

Volume 43, Issue 12 December 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-12>

[Reviewed earlier]

**PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 25 Jan 2026)  
[No new digest content identified]

**PLoS Genetics**  
<https://journals.plos.org/plosgenetics/>  
(Accessed 25 Jan 2026)  
[No new digest content identified]

**PLoS Global Public Health**  
[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)  
(Accessed 25 Jan 2026)  
**[The role of the media in the coverage of childhood vaccination in children under two years of age in Peru, ENDES 2021–2024](#)**  
Marcelo Cárdenas, Cirene Santana, Alejandra Castro, Antony Gonzales, Guillermo Salvatierra  
Research Article | published 23 Jan 2026 PLOS Global Public Health  
<https://doi.org/10.1371/journal.pgph.0005891>

**PLoS Medicine**  
<https://journals.plos.org/plosmedicine/>  
(Accessed 25 Jan 2026)  
**[The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study](#)**  
Ayaka Monoi, Akira Endo, Simon R. Procter, Sequoia I. Leuba, Stefan Flasche, Mark Jit, Maternal RSV Vaccine Benefit-Risk Advisory Group  
Research Article | published 20 Jan 2026 PLOS Medicine  
<https://doi.org/10.1371/journal.pmed.1004625>

**PLoS Neglected Tropical Diseases**  
<http://www.plosntds.org/>  
(Accessed 25 Jan 2026)  
[No new digest content identified]

**PLoS One**  
<http://www.plosone.org/>  
[Accessed 25 Jan 2026]  
[No new digest content identified]

**PLoS Pathogens**  
<http://journals.plos.org/plospathogens/>  
[Accessed 25 Jan 2026]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States**  
December 16, 2025 vol. 122 no. 50

<https://www.pnas.org/toc/pnas/122/50>

[Reviewed earlier]

### **PNAS Nexus**

Volume 4, Issue 11, November 2025

<https://academic.oup.com/pnasnexus/issue/4/11>

[Reviewed earlier]

### **Prehospital & Disaster Medicine**

Volume 40 - Issue 5 - October 2025

<https://www.cambridge.org/core/journalsprehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

### **Preventive Medicine**

Volume 200 November 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/200/suppl/C>

[Reviewed earlier]

### **Proceedings of the Royal Society B**

Volume 292, Issue 2060 December 2025

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

### **Public Health**

Volume 249 December 2025

<https://www.sciencedirect.com/journal/public-health/vol/249/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

### **Public Health Reports**

Volume 140 Issue 5-6, Sep-Oct/Nov-Dec 2025

<https://journals.sagepub.com/toc/phrg/140/5-6>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 35 Issue 13, November 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

## **Research Ethics**

Volume 21 Issue 4, October 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

## **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Revista Panamericana de Salud Pública/Pan American Journal of Public Health**

### **(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

## **Risk Analysis**

Volume 45, Issue 11 Pages: 3331-4076 November 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

## **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Royal Society Open Science**

Volume 12, Issue 12 1 December 2025

<https://royalsocietypublishing.org/toc/rsos/current>

[New issue; No digest content identified]

## **Science**

Volume 391| Issue 6783| 22 Jan 2026

<https://www.science.org/toc/science/current>

*Special issue - One year of Trump*

### **Damage assessment**

BY Jeffrey Mervis

22 Jan 2026: 338-341

Which of Donald Trump's changes are likely to last—and which will fade?

## [Pressure on the pipeline](#)

BY Katie Langin  
22 Jan 2026: 342-344

The Trump administration's agenda is likely to reshape the scientific workforce

## [Talking back](#)

BY David Malakoff  
22 Jan 2026: 345-347

An unprecedented assault has forced the U.S. scientific community to rethink its advocacy tactics

### *Editorial*

## [States pioneer a new frontier in US science funding](#)

BY Jeffrey Alexander  
Ivy Estabrooke  
22 Jan 2026

### *Policy Forum*

## [How malicious AI swarms can threaten democracy](#)

BY Daniel Thilo Schroeder, et al.

22 Jan 2026: 354-357

The fusion of agentic AI and LLMs marks a new frontier in information warfare

## **Science and Engineering Ethics**

Volume 31, Issue 6 December 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-6>

[Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 829| 17 Dec 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

## **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Social Science & Medicine**

Volume 386 December 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/386/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 46, Issue 6 December 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-6>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 68 November–December 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/68/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 11 Pages: 1145-1260 November 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 71 25 January 2026

<https://www.sciencedirect.com/journal/vaccine/vol/71/suppl/C>

*Short communication Abstract only*

### **[What happens when the CDC stops posting about measles on social media? An exploratory analysis of social media coverage during the 2025 measles outbreak](#)**

Amelia M. Jamison, Lauren M. Gardner

Article 128074

*Review article Open access*

### **[Population effects of influenza vaccination in children and adolescents: Systematic review](#)**

Mona Askar, Karam Adel, Madeleine Batke, Yuan Chi, ... Thomas Harder

Article 128040

*Research article Open access*

### **[Geospatial inequalities in zero-dose vaccination and structural determinants: Insights from sub-Saharan Africa \(2015–2023\)](#)**

Handan Wand, Sarita Naidoo, Jayajothi Moodley, Vaneshree Govender

Article 128062

*Book review*

### **[Rabies: Scientific Basis of the Disease and Its Management, 5th Edition Editors: Alan Jackson and Anthony Fooks](#)**

David Warrell, Mary Warrell

Article 128100

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 25 Jan 2026]

[No new digest content identified]

## **Value in Health**

December 2025 Volume 28 Issue 12 p1785-1932

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

## **World Medical Journal – Official Journal of The World Medical Association**

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

## **World Development**

Volume 196 December 2025

<https://www.sciencedirect.com/journal/world-development/vol/196/suppl/C>

[Reviewed earlier]

::::::

::::::

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

::::::

::::::

### **Pre-Print Servers**

#### **arXiv**

<https://arxiv.org/>

[Accessed 25 Jan 2026]

[*Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics*]

[Pre-print server analysis will resume with next week's edition]

#### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 25 Jan 2026]

[*Filter: All articles*]

[Pre-print server analysis will resume with next week's edition]

#### **medRxiv**

<https://www.medrxiv.org/content/early/recent>

[Accessed 25 Jan 2026]

[*Filter: All articles*]

[Pre-print server analysis will resume with next week's edition]

## OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[Pre-print server analysis will resume with next week's edition]

## Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 25 Jan 2026]

[Pre-print server analysis will resume with next week's edition]

\* \* \* \*

## Think Tanks

### Brookings [to 25 Jan 2026]

<http://www.brookings.edu/>

Research, Events

Research

#### [\*\*The HAIP Reporting Framework: Its value in global AI governance and recommendations for the future\*\*](#)

Miranda Bogen, Cameron F. Kerry, Karen Kornbluh, Joshua P. Meltzer, Marcel Mir Teijeiro, Enkhjin Munkhbayar, Nitya Nadgir, Elham Tabassi, Brooke Tanner, and Valerie Wirtschafter

January 21, 2026

The Hiroshima AI Process (HAIP) Framework marks a significant advancement in international AI governance. The G7-backed mechanism allows organizations to disclose their risk-mitigation practices for advanced AI systems.

Its first reporting cycle shows that the documentation process provides both internal and external value for companies, and the framework's broad flexibility enables diverse participation. However, it also limits comparability and creates uncertainty regarding purpose, audience, and use.

To reach its full potential, the report offers a set of recommendations for the framework to build on its documented success and to clarify its role within the broader AI governance ecosystem.

Research

#### [\*\*Africa's moment to shape the global order\*\*](#)

Landry Signé, Acha Leke, and Mayowa Kuyoro

January 14, 2026

### Center for Global Development [25 Jan 2026]

<https://www.cgdev.org/>

All Research

POLICY PAPER

#### [\*\*A Roadmap for Strengthening and Diversifying Regulatory Pathways in Africa\*\*](#)

Javier Guzman and Ainhoa Petri-Hidalgo

January 15, 2026

The global regulatory architecture has delivered important gains in access to essential health products, but it's out of step with today's priorities: expanding local manufacturing, improving regional supply resilience, and accelerating access to products that meet region-specific needs. The system ...

**Chatham House** [to 25 Jan 2026]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

**[Trump vs Carney at Davos: One summit, two visions | Independent Thinking podcast](#)**

President Trump proclaimed US strength and denigrated Europeans. Canadian Prime Minister Mark Carney urged smaller nations to adapt to the 'new reality' by building coalitions with partners who share values. Audio

Published 23 January 2026 35 minute listen

*Featured content*

*Expert comment*

**[Iran's internet shutdown signals a new stage of digital isolation](#)**

The widespread blackout in response to protests reflects the Iranian regime's dangerous embrace of digital isolation as a long-term strategy of repression.

23 January 2026 4 minute READ

**Council on Foreign Relations** [25 Jan 2026]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 25 Jan 2026]

<https://www.csis.org/>

*Reports [Selected]*

**[Profit from Preparation: Innovations and Opportunities in Disaster Risk Financing in Developing Countries](#)**

A combination of extreme weather impacts and cuts to aid budgets mean that the next few years will be ripe for the rapid development and further scaling up of anticipatory action measures and prearranged finance approaches to better manage mounting disaster risk.

Report by Noam Unger and Madeleine McLean — January 12, 2026

**McKinsey Global Institute** [to 25 Jan 2026]

<https://www.mckinsey.com/mgi/overview>

*Featured Research*

*No new digest content identified.*

**ODI** [Overseas Development Institute] [to 25 Jan 2026]

<https://odi.org/en/publications/>

*Publications [Selected]*

**[Improving financial access for non-profit organisations: what we have learned, and the road ahead](#)**

13 January 2026

Meeting/conference report

**Pew Research Center** [to 25 Jan 2026]

<https://www.pewresearch.org/>

*Latest Publications*

*short reads* Jan 13, 2026

**Wikipedia at 25: What the data tells us**

As of December 2025, there are over 66 million articles across all languages on Wikipedia. Around 7 million articles are in English.

**Rand** [to 25 Jan 2026]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

**School-entry Vaccine Exemptions in Maine Before and After Public Law 154, 2018-2023**

We examined how this policy change affected vaccine exemption rates and clustering in kindergartens.

*Research Jan 20, 2026*

Maine passed Public Law (PL) 154 in 2020, eliminating new non-medical exemptions (NMEs) to school-entry immunization requirements. We examined how this policy change affected vaccine exemption rates and clustering in kindergartens using annual, publicly available school-level counts of vaccine exemptions from the Maine Center for Disease Control and Prevention. Although NMEs decreased significantly, medical exemptions (MEs) increased and began clustering in kindergartens after PL 154's implementation in 2021. This perpetuated the increased likelihood that children with exemptions, primarily MEs post-PL 154, interact with one another in school. The emergence of clusters of kindergartens with statistically significantly higher ME rates relative to the population average may create or reinforce existing under-immunized pockets at higher risk of vaccine-preventable diseases. Our results demonstrate that eliminating NMEs can substantially reduce overall school-entry vaccine exemption rates, while underscoring the need for additional guidance to support states in implementing these policy changes.

**Scaling Pandemic Preparedness and Response Cost Estimates for Disease Transmission Modes**

In this paper, the authors aim to understand what the world needs to spend annually to prepare for and respond to emerging respiratory pandemic diseases resulting from different modes of transmission: respiratory, insect-vectored, and fluid-borne.

*Expert Insights Jan 13, 2026*

...The G20 HLIP report proposes funding and governance mechanisms to ensure that surge financing is available when and where it is needed most (G20 HLIP, 2025). The 2025 report bases its estimates of surge financing needs on previously published retrospective analyses of preparedness and response spending during COVID-19, a disease that spreads via the respiratory route. We investigated whether those funding mechanisms could be scaled for pandemic scenarios that are expected to vary in their effects on populations and infrastructure. Our analysis seeks to determine whether and, if so, how those costs would differ for pandemics spreading through populations via other transmission modes...

**Urban Institute** [to 25 Jan 2026]

<https://www.urban.org/research>

*New Research Publications - Selected*

*No new digest content identified.*

**World Economic Forum** [to 25 Jan 2026]

<https://agenda.weforum.org/press/>

Media [Selected]

## **Global Risks Report 2026: Geopolitical and Economic Risks Rise in New Age of Competition**

News 14 Jan 2026

:: Geoeconomic confrontation emerges as the top global risk for 2026, climbing eight positions in the two-year outlook, as economic risks rise fastest in the short term – with downturn and inflation both surging eight positions year-on-year.

:: AI anxiety soars while environmental risks declined in ranking in the short term.

:: Global outlook remains uncertain: half of experts expect a turbulent or stormy global outlook; only 1% anticipate calm.

..."A new competitive order is taking shape as major powers seek to secure their spheres of interest. This shifting landscape, where cooperation looks markedly different than it did yesterday, reflects a pragmatic reality: collaborative approaches and the spirit of dialogue remain essential," said Børge Brende, President and CEO, World Economic Forum. "Our Annual Meeting in Davos will serve as a vital platform for understanding risks and opportunities and for building the bridges needed to address them."

"The Global Risks Report offers an early warning system as the age of competition compounds global risks – from geoeconomic confrontation to unchecked technology to rising debt – and changes our collective capacity to address them. But none of these risks are a foregone conclusion," said Saadia Zahidi, Managing Director, World Economic Forum. "The challenges highlighted in the report underscore both the scale of the potential perils we face and our shared responsibility to shape what comes next..."

:::::

:::::

## ***Public Consultations/Call for Inputs/Call for Papers***

### **Request for Information on Draft NIH Controlled-Access Data Policy and Proposed Revisions to NIH Genomic Data**

NATIONAL INSTITUTES OF HEALTH ([NIH](#)) Notice Number: NOT-OD-26-023 **Response Date:**

**March 18, 2026**

#### *Purpose*

The National Institutes of Health (NIH) is requesting public input on its proposal to establish harmonized and transparent policy requirements for protecting human participant research data. Specifically, NIH proposes (1) establishing policy requirements for which data should be controlled-access under NIH data sharing policies, and (2) revising the NIH Genomic Data Sharing Policy to simplify and harmonize requirements.

#### *Background*

NIH serves as the steward of a wide range of research data and continuously works to optimize open sharing with appropriate protections throughout the entire data lifecycle. Given its numerous established data policies, NIH is proposing a holistic update to its data policy framework to strengthen data protections, clarify requirements, and reduce duplicative burden.

NIH is proposing a new NIH Controlled-Access Data Policy to support the research community in fulfilling NIH data sharing expectations. This proposed policy specifies human participant data types required to be managed via controlled-access and provides criteria for assessing the need for controls for other data types. It also provides a standard set of expectations across NIH Institutes, Centers and Offices to promote maximal responsible human participant data sharing through controlled access while simultaneously responding to emergent privacy and security risks, including those outlined in the following security directives...

## **Working Group XV – Pharmacoepidemiology for Public Health - PUBLIC CONSULTATION** **DRAFT REPORT**

Pharmacoepidemiology aims to appraise and understand the use and effects — both beneficial and adverse — of medicines in real-world settings. As such it can be considered a bridge science, linking clinical pharmacology, epidemiology, public health and the social sciences.

Medicines are public health tools. With regard to the quality and transparency of the assessment of their effectiveness and safety, they are increasingly subject to the expectations and requirements of patients, healthcare professionals and regulators. Those involved in the development and delivery of medicines must therefore take full account of the aforementioned paradigm shifts. Additionally, the arrival of novel therapeutic agents, such as gene therapy, biologics and mRNA vaccines, whose modes of action and interactions with living organisms have very little in common with those of the more traditional chemical medicines, has brought into question the classic elements of pharmacovigilance and pharmacoepidemiology, such as the dose–effect relationship, drug causation criteria and the determination of drug exposure.

CIOMS full [concept note on Pharmacoepidemiology for Public Health](#)

You are invited to review and comment on the draft report entitled *Realising the Potential of Pharmacoepidemiology for Public Health Decision-Making*. [Download the report here](#).

Please note that comments will only be considered when using the [template provided here](#). The **deadline to submit your comments is 13 March 2026**.

\* \* \* \*

### ***Contents [click to move among sections]***

[:: Milestones, Perspectives](#)  
[:: WHO](#)  
[:: Organization Announcements](#)  
[:: Journal Watch](#)  
[:: Pre-Print Servers](#)

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

:::::::

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*